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Abstract 
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Abstract 
We identified the four-and-a-half LIM domain protein 2 (FHL2) as a novel 
regulator of CCL19-induced dendritic cell (DC) migration. Initiation of migration 
is a hallmark of DC function and plays a central role in the induction and 
regulation of immune responses. In vivo, DCs continuously acquire Ag in the 
periphery and migrate to draining LNs, under the influence of local 
environmental chemotactic factors like CCL19/21 or sphingosine 1-phosphate 
(S1P). We investigated the role of S1P- and RhoA regulated FHL2 in this 
process.  
We found reduced nuclear localization of FHL2 in mature bone marrow-derived 
DCs (BMDCs), compared with immature BMDCs, following stimulation with 
CCL19. Furthermore, in vitro-generated murine FHL2-/- BMDCs displayed a 
significantly increased migratory speed, directionality, and migratory persistence 
toward the chemokine CCL19 compared with wild-type BMDCs. Moreover, in 
vivo, FHL2-/- BMDCs showed increased migration toward lymphoid organs. 
FHL2-/- BMDCs increased the expression of S1P receptor 1, which was 
associated with greater Rac activation. An S1PR1 antagonist and knock-down 
of S1PR1 abrogated the increased migratory speed of FHL2-/- BMDCs. Our 
results identify FHL2 as an important novel regulator of DC migration via 
regulation of their sensitivity toward environmental migratory cues like S1P and 
CCL19. 
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Zusammenfassung 
Dendritische Zellen (DZ) spielen eine entscheidende Rolle in der Initiierung und 
Regulierung adaptiver und angeborener Immunantworten. In der Peripherie 
nehmen unreife DZ ständig Antigen auf, prozessieren es und wandern zu den 
drainierenden Lymphknoten, um T Zellen ihr spezifisches Antigen zu 
präsentieren. Die Migration der DZ zu den Lymphknoten spielt eine wichtige 
Rolle in der Ausübung ihrer Aufgabe als Antigen präsentierende Zellen. Man 
weiß, dass das Aktin Zytoskelett bei der Ausübung von Migration eine 
entscheidende Rolle spielt. Wir haben herausgefunden, dass das Four-and-a-
half-Lim only protein (FHL2), das an Integrinen bindet und als Koaktivator von 
Transkriptionsfaktoren wirkt, an der Zellmigration von DZ beteiligt ist.  
FHL2 findet sich in reifen aus murinen Knochenmark gewonnen dendritischen 
Zellen (KMDZ) nach Stimulation mit CCL19 an der Membran statt im Zellkern 
wieder, wie es bei immaturen KMDZ der Fall ist. Geschwindigkeit, Direktionalität 
und Persistenz von aus FHL2-defizienten KMDZ ist in vitro  und in vivo 
signifikant erhöht. FHL2-/- prägen nicht konstitutiv den Chemokin Rezeptor 
CCR7, andere Maturationsmarker aus oder erhöhte Zytokin Produktion. 
Weiterhin hat FHL2 keinen Einfluss sowohl auf Rezeptor vermittelte als auch 
pinozytotische Antigenaufnahme und Präsentation von Ovalbumin zu T Zellen. 
Dafür weisen FHL2-defiziente KMDZ morphologisch einen reifen Phänotyp auf. 
Der Sphingosin-1-Phosphat Rezeptor 1ist in FHL2-/- KMDZ erhöht, was wohl zu 
einer höheren Rac Aktivierung führt. 
Anhand dieses Models wird zum ersten Mal ein Mechanismus beschrieben, der 
migratorische Geschwindigkeit unabhängig von der DZ Maturierung kontrolliert. 
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1. Introduction 
 
1.1 Cell migration 
Cell migration plays a central role in both normal and pathological processes, 
including embryonic development, wound healing, tumor metastasis, and 
inflammation (Chan et al., 2007). For example, leucocytes move toward 
inflammation, infection and injury, guided by gradients of chemokines or 
bacterial products. Angiogenic endothelial cells migrate toward ischaemic 
tissues which produce growth factors, such as vascular endothelial growth 
factor (VEGF). Fibroblasts migrate toward platelet-derived growth factor (PDGF) 
and other factors produced in wounds to facilitate healing. In metastasis, tumor 
cells migrate from the initial tumor mass into the circulatory system, which they 
subsequently leave and migrate into a new site (Moissoglu and Schwartz, 
2006). Cell migration is a multistep process involving changes in the 
cytoskeleton, cell-substrate adhesions and the extracellular matrix (ECM) which 
will be discussed below. 
 
1.1.1 The Cytoskeleton 
In most animal cells, the cytoskeleton is the essential component in creating 
motility-driving forces, and in coordinating the entire process of movement. The 
cytoskeleton is a polymer network, composed of three distinct biopolymer types: 
actin, microtubules (MT) and intermediate filaments (IF), which are 
differentiated principally by their rigidity (Ananthakrishnan and Ehrlicher, 2007). 
Actin is the most abundant protein in many eukaryotic cells, which is arranged 
in semiflexible polymers (Gittes et al., 1993). The filaments are double helical 
polymers of globular subunits all arranged head-to-tail to give the filament a 
molecular polarity (Fig. 1.1), whereas growth at the barbed end is favored over 
the other and actin filaments in cells are strongly oriented with respect to the 
cell surface, barbed ends outward (Pollard and Borisy, 2003).  
Introduction 
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MTs are the stiffest of the biopolymers (Dogterom et al., 2005) and exhibit 
similar dynamics to those of actin: They are functionally polar, treadmill, and 
can impart a force through polymerization. IFs are much more flexible than actin 
filaments and MTs. There are different classes of IFs such as vimentin, desmin, 
keratin, lamin and neurofilaments. Unlike actin filaments or MTs, IFs are not 
polarized, do not treadmill, do not generally depolymerize under physiological 
conditions. 
 
These three kinds of biopolymers build an internal cellular scaffold, known as 
the cytoskeleton − an organized and coherent structure that is formed by 
connecting these filaments via entanglements, and also crosslinking, bundling, 
binding motor and other proteins. These cytoskeletal assemblies then work 
together as a composite, dynamic material in cell functions such as structural 
integrity, shape, division, and organelle transport and cell motility. With respect 
to motility, although the other polymer assemblies in the cell also aid in 
coordinating movement and powering translocation, the actin cytoskeleton is 
regarded as the essential engine that drives cell protrusion, the first step of 
movement (Ananthakrishnan and Ehrlicher, 2007). 
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Figure 1.1: The dendritic nucleation model of actin dynamics at the leading edge of 
motile cells. Top: the barbed end branching model. (1) The branching complex made of G-
actin, Arp2/3, and WASP/N-WASP (or WAVE isoforms) binds to the barbed end of the filament. 
This incorporation is mediated by the actin subunit of the branching complex. (2) Arp2/3 
nucleates a lateral branch. The growth of the filaments drives membrane protrusion. (3) ATP 
hydrolysis on Arp2 induces debranching. (4) After depolymerization of the branched filament, 
Arp2/3 and actin are released. (5) Nucleotide exchange is required to recycle actin and Arp2/3. 
Bottom: the side branching model. This model proposes that Arp2/3 activated by the COOH-
terminal domain of WASP/N-WASP (or WAVE isoforms) binds to the side of an actin filament. In 
this activated state, Arp2-Arp3-G-actin mimics an actin nucleus to initiate a lateral branch (Le 
Clainche and Carlier, 2008).  
 
 
1.1.2 Components and structure of the actin cytoskeleton 
Actin filaments in vivo can assemble into different structures such as networks 
and bundles, which is carried out with the help of numerous accessory proteins 
(Pollard et al., 2000). Cells contain a pool of unpolymerized actin monomers, 
globular actin (G-actin), bound to profilin and thymosin-β4. Signaling pathways 
activate nucleation-promoting factors such members of the Wiskott-Aldrich 
Syndrome Protein (WASp) family of proteins to stimulate Actin-Related 
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Proteins2/3 (Arp2/3) complex to initiate a new filament in 70° angle (Fig. 1.1; 
Amann and Pollard, 2001). Cofilin facilitates subunit dissociation from the 
pointed end of actin filaments and induces filament severing and is essential for 
promoting filament treadmilling at the front of migrating cells. Also, actin 
filaments themselves bind Adenosine-5'-triphosphate (ATP), and hydrolysis of 
ATP stimulates destabilization of the polymer (Le Clainche and Carlier, 2008; 
Pollard and Borisy, 2003). All these proteins and many more work together to 
coordinate actin network formation and bring about leading edge motility in 
several steps. 
 
Although multicellular organisms contain a wide array of actin filament 
assemblies, the actin structures that play fundamental roles in cell migration can 
be roughly divided into three categories: lamellipodial actin network at the 
leading edge of the cell, unipolar filopodial bundles beneath the plasma 
membrane, and contractile actin stress fibers in the cytoplasm (Ridley et al., 
2003). 
The lamellipodium contains a network of short, branched actin filaments that 
produce the physical force for protrusion of the leading edge. The formation of 
new actin filaments at the leading edge is promoted by the Arp2/3 complex 
(Mullins et al., 1998; Svitkina and Borisy, 1999). Filopodia are thin cellular 
processes organized into long parallel bundles rope-like bundles (Welch and 
Mullins, 2002).  
In contrast to relatively well characterized lamellipodia and filopodia, the 
assembly mechanisms of actin stress fibers are still poorly understood. Stress 
fibers are contractile actomyosin bundles, which are essential for cell adhesion 
to the substratum and for changes in cell morphology, specifically the retraction 
of the trailing edge during migration. Stress fibers are composed of relatively 
short actin filaments with alternating polarity (Hotulainen and Lappalainen, 
2006). 
 
1.1.3 Pushing the cell forward 
After sensing the signal, the cell starts moving in response to the signal. If the 
signal is a chemoattractant, actin polymerizes in the region of the cell closest to 
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the signal, whereas if the signal is a chemorepellant, the cell moves away by 
polymerizing actin in the opposite side. As the extending edge moves forward, 
the cell constantly monitors the signal direction and tailors its direction of motion 
accordingly. The central dogma of cell motility divides movement into four 
sequential steps (Fig. 1.2).  
To migrate, cells must acquire a spatial asymmetry enabling them to turn 
intracellularly generated forces into net cell body translocation, i.e. a clear 
distinction between cell front and rear (Sullivan et al., 1984). Long, flexible actin 
filaments cannot sustain a pushing force without buckling. Cells overcome this 
problem by creating a dense array of short-branched filaments namely 
lamellipodia and filopodia, respectively. The membrane does not remain 
stationary but undergoes constant Brownian motion i.e. random thermal 
fluctuation. Polymerization of actin filaments towards the cell membrane at the 
leading edge can subsequently apply an elastic force on the membrane and 
push it forward. Actin filaments move rearward with respect to the substrate, 
and generally in a direction opposite to the movement of the cell, known as 
retrograde flow (Ananthakrishnan and Ehrlicher, 2007; Lauffenburger and 
Horwitz, 1996).  
 
 
Figure 1.2: The central dogma of cell motility divides movement into four sequential 
steps. Cells (1) extend a lamellipodium at the leading edge, (2) make new adhesive contacts, 
(3) contract to move the cell body forward, and (4) detach the trailing edge. These attachments 
prevent the protruding leading edge from retracting. Thus forward movement requires that new 
adhesive contacts form at the leading edge and old ones break in the trailing edge (Ridley, 
2001). 
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1.1.4 Small Rho GTPases 
Many different intracellular signaling molecules have been implicated in cell 
migration, including Ca2+-regulated proteins, mitogen-activated protein kinase 
cascades, protein kinases C, phosphatidylinositide kinases, phospholipases C 
and D, and tyrosine kinases (Ridley, 2001). However, one particular family of 
proteins seems to play a pivotal role in regulating the biochemical pathways 
most relevant to cell migration, the Ras homolog gene family (Rho) guanosine 
triphosphate (GTP)ases (Raftopoulou and Hall, 2004). 
Rho-family proteins make up a major branch of the Ras superfamily of small 
GTPases. All members contain sequence motifs characteristic of all GTP-
binding proteins, and are thought to cycle between active GTP-bound and 
inactive guanosine diphosphate (GDP)-bound states. The GDP/GTP cycling of 
Rho-family proteins is controlled mainly by three distinct functional classes of 
regulatory protein: Guanine nucleotide exchange factors (GEFs), GTPase 
activating protein (GAPs), and Guanine nucleotide dissociation inhibitors (GDIs) 
(Figure 1.3). When bound to GTP, they are active and interact with their 
downstream target proteins, which include protein kinases, lipid-modifying 
enzymes, and activators of the Arp2/3 complex (Charest and Firtel, 2007; 
Raftopoulou and Hall, 2004). 
 
Figure 1.3: Three distinct regulatory proteins control GDP/GTP cycling. GEFs stimulate the 
weak intrinsic exchange activity of Rho-family proteins to promote an exchange of the bound 
GDP for GTP; GAPs stimulate the intrinsic GTP hydrolysis activity of Rho-family proteins and 
thereby promote formation of the inactive GDP-bound protein and GDIs inhibit Rho proteins by 
blocking nucleotide exchange, and thus the binding of effectors and GAPs to GTP-bound Rho 
GTPases (Wennerberg and Der, 2004). 
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Rho GTPases are pivotal regulators of actin and adhesion organization and 
control the formation of lamellipodia and filopodia. The major targets for Ras-
related C3 Botulinum Toxin Substrate (Rac) and Cell Division Cycle 42 
(CDC42) that mediate actin polymerization in protrusions are the WASP/ 
WASP-family verprolin-homologous protein (WAVE) family of Arp2/3 complex 
activators (Cory and Ridley, 2002). Rac stimulates Arp2/3-complex-induced 
actin polymerization by interacting with a complex of insulin receptor tyrosine 
kinase substrate p53 (IRSp53) and WAVE proteins. Rac can also induce actin 
filament uncapping by generating phosphatidylinositol 4,5-bisphosphate locally 
or, Rac acts via p21-activated kinases to stimulate LIM domain kinase, which 
inhibits cofilin-induced actin depolymerization (Ridley, 2001).     
The interaction of CDC42 with WASP together with binding to 
phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2), relieves the autoinhibited 
conformation of WASP proteins and subsequently leads to activation of the 
ARP2/3 complex (Mattila and Lappalainen, 2008; Svitkina et al., 2003). 
Stress fiber assembly is regulated by a signaling cascade involving the RhoA 
small GTPases. The GTP bound form of RhoA activates Rho-associated kinase 
(Friedl and Brocker, 2000), which in turn promotes stress fiber formation by 
inhibiting actin filament depolymerization and by inducing contractility 
(Hotulainen and Lappalainen, 2006; Jaffe and Hall, 2005). 
 
1.2 The immune system 
Vertebrates have developed systems of immune defense enabling them to cope 
with the constant threat posed by environmental pathogens. The mammalian 
immune system represents a multilayered defense system comprising both 
innate and adaptive immune responses, characterized by the increasing 
complexity of their antigen-recognition systems (Moser and Leo, 2010). 
Innate immunity uses the genetic memory of germline-encoded receptors to 
recognize the molecular patterns of common pathogens (Janeway and 
Medzhitov, 2002). Adaptive immunity, akin to somatic memory, is a complex 
system by which the body learns to recognize a pathogen's unique antigens 
and builds an antigen specific response to destroy it. The effective development 
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of the overall immune response depends on careful interplay and regulation 
between innate and adaptive immunity.  
 
1.2.1 Innate versus adaptive immunity 
Cells of the innate immune system are able to detect an invading pathogen 
through a limited set of germ-line encoded receptors. The innate immune 
system uses various Pattern recognition receptors (PRRs) that are expressed 
on the cell surface, in intracellular compartments, or secreted into the blood 
stream and tissue fluids and recognize a series of conserved molecular 
structures expressed by pathogens. These pathogen-associated molecular 
patterns (PAMPs; Akira et al., 2006) are distinctive for a set of pathogens and 
include components of microbial membranes, cell walls, proteins, 
deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). On the basis of 
function, PRRs may be divided into endocytic PRRs or signaling PRRs. 
Signaling PRRs include the large families of membrane-bound Toll-like 
receptors (TLRs) and cytoplasmic NOD-like receptors (Medzhitov, 2001). 
Endocytic PRRs promote the attachment, engulfment and destruction of 
microorganisms by phagocytes, without relaying an intracellular signal.  
Due to the limited diversity of PRRs, pathogens displaying a high mutation rate 
can easily escape recognition from the innate immune system (Bowie and 
Unterholzner, 2008). Moreover, the ability of several pathogens such as viruses 
to replicate intracellularly renders their detection and elimination particularly 
challenging. The adaptive immune system constitutes a humoral and cellular 
part, B cells and T cells, respectively, which show high specificity and are at the 
same time very versatile due to their expression of receptors recognizing non-
conserved molecules. The possibility of the T and B cell receptor to undergo 
genetic recombination allows a small number of genes to form a nearly infinite 
number of receptors which will then be able to recognize a molecule never 
encountered before. B cells can also undergo somatic hypermutation which 
makes antibodies more and more specific and increases their affinity over time. 
Importantly, the adaptive immune response is able to form a memory, 
conferring life long protection from the respective pathogen to the organism. 
However, cells of the adaptive immune system cannot reliably discriminate 
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between self and non-self with potentially deleterious consequences to the 
organism. Therefore adaptive immune responses must be educated by the 
innate immune system and tightly controlled (Palm and Medzhitov, 2009). Any 
conversation between innate and adaptive immunity requires accurate and 
effective translation of the innate signals of infection or damage. Central to this 
translation is the dendritic cell (DC). 
 
1.2.2 Dendritic cells 
DCs next to macrophages and B cells belong to professional antigen presenting 
cells (APC). DC are the most potent APC that facilitate T cell activation and play 
a major role in the initiation and regulation of innate and adaptive immune 
responses to antigens (Kikuchi et al., 2005). They are a heterogeneous 
population that are derived from bone marrow (BM) progenitors, which may 
differentiate into circulating precursors that later home to peripheral tissue as 
immature myeloid DC (Sánchez-Sánchez et al., 2006). Myeloid DC are found in 
an immature state in epithelia and in the interstitial space of most solid organs 
(Sánchez-Sánchez et al., 2006) where they constantly sample their 
microenvironment for foreign and host antigens (Burns et al., 2004). After 
antigen engulfment they turn from highly efficient antigen capturing cells into 
APC with the capacity to prime T cells after they have migrated to the draining 
lymph nodes (LN).  
 
1.2.3 Antigen uptake and processing 
Immature DCs endocytose avidly through a variety of mechanisms, including 
‘nonspecific’ uptake by constitutive macropinocytosis and ‘specific’ uptake via 
receptor-mediated endocytosis and phagocytosis (Trombetta and Mellman, 
2005). Macropinocytosis represents a critical antigen uptake pathway allowing 
DCs to rapidly and nonspecifically sample large amounts of surrounding fluid. 
Phagocytosis, in contrast, is initiated by the engagement of specific receptors, 
triggering a cascade of signal transduction, which is required for actin 
polymerization and effective engulfment (Lanzavecchia, 1996). Receptor-
Introduction 
 
11 
 
mediated endocytosis allows the uptake of macromolecules through specialized 
regions of the plasma membrane, termed coated pits, and includes Fc, 
complement, heat shock proteins, scavenger and members of the c-type lectin 
family (Guermonprez et al., 2002).  
After antigen engulfment, DCs assemble small peptide epitopes of the pathogen 
or extracellular material in antigen–major histocompatibility complexes (MHC) 
and their skills to capture antigen declines (Johannessen et al., 2006). MHC 
molecules are cell-surface glycoproteins with a peptide-binding groove that 
allows intracellularly loaded peptides to be presented at the cell surface, where 
the combined ligand can be recognized by T cells receptors. There are two 
classes of MHC molecules, MHC class I and MHC class II, which bind peptides 
from proteins degraded in different intracellular compartments.  
MHC class I molecules bind peptides from proteins degraded in the cytosol i.e. 
derived from viruses and present these at the cell surface, where they are 
recognized by cluster of differentiation (CD)8 T cells (Banchereau and 
Steinman, 1998). These peptides which are usually 8 to 10 amino acids (aa) 
long are translocated into the endoplasmatic reticulum (ER) by a heterodimeric 
ATP-binding protein called transporters associated with antigen processing 
(TAP), and are then available for binding by partially folded MHC class I 
molecules that are held tethered to TAP (Ohl et al., 2004). In contrast, MHC 
class II molecules present peptides, which are at least 13 aa long, from 
pathogens and their products originating in the vesicular system to the cell 
surface, where they are recognized by CD4 T cells (Janeway et al., 2005). In 
addition, DCs have the ability to present exogenous antigens internalized 
through the endocytic pathway to CD8 T cells. The mechanisms responsible for 
so called cross-presentation are critical for initiating CD8 T cell responses to 
antigens that would not otherwise gain access to the MHC class I presentation 
pathway in DC (Jensen, 2007). 
 
1.2.4 Maturation 
The main function of DC in the induction of an adaptive immune response is to 
carry antigen from the periphery to lymphoid organs for presentation to T cells 
(Fig. 1.4). The interface between an APC and lymphocyte is called 
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immunological synapse, which consists of a central cluster of T cell receptors 
surrounded by a ring of adhesion molecule. 
A signal from pathogens, often referred to as a danger signal, induces DCs to 
enter a developmental program, called maturation, which transforms DCs into 
efficient APCs and T cell activators (Guermonprez et al., 2002). Immature DCs 
display a phenotype reflecting their specialized function as antigen-capturing 
cells. They are highly endocytic and express relatively low levels of surface 
MHC I and MHC II class molecules and costimulatory molecules such as CD80, 
CD86 and CD40 (Tan and O’Neill, 2005). Bacterial and viral products, as well 
as inflammatory cytokines and other nonself-molecules, induce DC maturation 
through direct interaction with specific DC surface receptors. The transition of 
immature to a mature DC is accompanied by a change of their phenotype which 
equips the DC to efficiently stimulate T cells. These phenotypic changes include 
increased production of MHC-peptide complexes, markers necessary of T cell 
binding, costimulatory molecules, and production of growth factors such as 
Interleukin-12 (IL-12), chemokines, and cytokines (Fig. 1.5; Steinman et al., 
2003). 
 
 
Figure 1.4: The migratory pathway of DC under steady-state and inflammatory 
conditions. DC reside in the periphery where continuously sample their environment for 
antigen. After antigen engulfment and concomitantly signaling via PRRs DC undergo a huge 
transition, which will equip them to present antigen to T cells in the draining LN. They highly 
upregulate CCR7 that will guide them the way towards CCL19 produced in the draining LN. 
 
Introduction 
 
13 
 
The interaction of naive T cells with DCs can lead to different forms of immune 
response depending on the type of DC and its activation state (Steinman et al., 
2003). Under steady state conditions, the outcome of T cell stimulation by DC 
can be apoptosis, anergy, or the development of regulatory T cells, which can 
result in T cell tolerance (Tan and O’Neill, 2005). Under conditions of infection 
or inflammation, DC encounter signals via TLR or other danger signals including 
proinflammatory cytokines and bacterial or viral products such as 
lipopolysaccharides (LPS), CpG motifs, and double-stranded RNA. These 
factors may induce maturation and activation of DC, rendering them 
immunogenic. 
The maturation state of DC is considered as a key determinant of the outcome 
of T cell activation leading to T cell tolerance or T cell immunity. DC with an 
immature phenotype are likely tolerogenic to T cells, and mature DC are 
immunogenic, but some level of maturation of DC is required for tolerance 
induction (Tan and O’Neill, 2005). 
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Figure 1.5: T cell stimulation requires three DC-derived signals. Signal 1 is the antigen-
specific signal that is mediated through T-cell receptor triggering by MHC class-associated 
peptides processed from pathogens after internalization through PRRs. Signal 2 is the 
costimulatory signal, mainly mediated by triggering of CD28 by CD80 and CD86 that are 
expressed by DCs after ligation of PRRs. Signal 3 is the polarizing signal that is mediated by 
various soluble or membrane-bound factors, such as IL-12 (Kapsenberg, 2003). 
 
 
1.2.5 The migratory phenotype of DC 
During the process of migration also the morphology of DC changes. Migration 
of DC from sentinel sites to lymphoid tissue entails the initiation and 
coordination of a complex series of cytoskeletal rearrangements resulting in 
polarized protrusion, formation of new adhesion points, and detachment (Burns 
et al., 2004). Immature DCs are characterized by a relatively small cell body, 
but very long membrane processes. These processes are known as filopodia 
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and are involved in anchorage to ECM. The dendrites are temporarily retracted 
during DC migration, as immature DC differentiate into the mature state after 
antigen uptake. DC morphology in the periphery is believed to increase the 
efficiency of antigen contact and uptake, while within lymphoid tissue it may 
maximize contact with T cells (Swetman et al., 2002). After antigen capture with 
subsequent migration to the LN, filopodia vanish, the membrane ruffles, 
lamellipodia and veils develop, which assist in detachment from the surface 
(Calle et al., 2004). 
In stark contrast to the situation found in the majority of resident connective 
tissue cells, migrating DCs possess neither stress fibers nor large focal 
adhesions. Instead, the cytoplasm contains a delicate tracery of microfilament 
bundles that concentrate at a series of discrete foci at the substratum interface 
termed podosomes (Adams, 2002). DCs, like all leukocytes, use amoeboid cell 
migration mechanisms to traffic within peripheral and lymphoid tissues (Friedl 
and Weigelin, 2008). Amoeboid migration is characterized by the acquisition of 
cell polarity, which then drives the development of a leading edge followed by 
the cell body and a posterior tail known as the uropod. Generally, polarization 
occurs in response to migration-promoting factors such as chemokines, which 
signal via G protein-coupled receptors. 
The formation of protrusions at the leading edge of DC is controlled by Rac and 
Cdc42 (Swetman et al., 2002), whereas Rho signaling regulates cytoskeletal 
reorganization upon DC maturation leading to cell contraction at the trailing 
edge of cells. Furthermore, Cdc42 activity is associated with the formation of 
filopodia in immature DC, while Rac activity induces the loss of filopodia and 
formation of lamellipodia in mature DC. This formation of lamellipodia in mature 
DC is thought to allow their rapid migration into the secondary lymphoid organs 
(Burridge and Wennerberg, 2004).  
 
Mechanistically, it was believed that migration of leukocytes, including DCs, 
relied upon interactions between surface receptors, such as integrins, and their 
ligands in the extracellular environment. However, it was demonstrated that DC 
locomotion occurred through alignment of the cell body to surrounding cell 
surfaces and/or ECM proteins independently of integrins (Lammermann et al., 
2008). Rather, cell movement is achieved by ‘squeezing and flowing’ of the 
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actin cytoskeleton, a process that appears to utilize weak-to-non-adhesive 
interactions and thus propels the DC along the path of least resistance towards 
the polarizing agent (Roediger et al., 2008). 
 
1.2.6 Chemokine, CC Motif, receptor 7 (CCR7) 
During the maturational processes, DCs also change their surface expression 
profile of chemokine receptors. Chemokines are small proteins that can bind G 
protein-coupled chemokine receptors (Yanagawa and Onoe, 2002), that confer 
DC the ability to detect and move directionally toward a chemotactic stimulus 
(Riol-Blanco et al., 2005). 
During the migration to the draining LN under inflammatory as well as under 
steady-state conditions, DC chemokine receptors CCR2 or CCR5 are 
downregulated that facilitate entry into inflamed tissues, while CCR7 is 
upregulated (Sallusto et al., 1998). CCR7 is essential for DC migration into 
dermal lymphatics and guidance to the draining LN (Ohl et al., 2004; Saeki et 
al., 1999). CCR7 has two ligands, chemokine, CC MOTIF, ligand 19 (CCL19) 
and CCL21 that are highly expressed by stromal cells in the T cell rich areas in 
the LN (Sánchez-Sánchez et al., 2006), endothelial cells, and DCs themselves 
(MartIn-Fontecha et al., 2003), and they each participate in the migration of DCs 
from peripheral tissues like skin to LNs (Robbiani et al., 2000). Because the two 
CCR7 ligands, CCL19 and CCL21, are expressed in the T cell area of 
secondary lymphoid organs, DCs migrate toward these ligands and finally 
aggregate in afferent lymphatic vessels and the T cell area of secondary 
lymphoid organs (Dieu-Nosjean et al. 1999).  
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1.3 Four-and-a-half lim domains 2 (FHL2) 
FHL2 belongs to the family of Four-and-a-half LIM only proteins which consist of 
five members: FHL1–4 and Activator of CREM in testis (ACT). Common 
synonymes are SLIM 3 and DRAL standing for ‘Downregulated in 
Rhabdomyosarcoma Lim Protein’, which how it was called by Genini et al. 
(1997), because they used subtractive cloning to isolate a gene that is 
downregulated during transformation of normal myoblasts to 
rhabdomyosarcoma cells. 
 
1.3.1 Structure and expression of FHL2 
The FHL2 gene encodes a 279 aa polypeptide with an observed mass of 32kD 
(Morgan and Madgwick, 1996), which was confirmed by Muller et al. (2000) and 
El Mourabit et al. (2003). The protein sequence contains four complete LIM 
domains and the second half of a fifth LIM domain (Fig. 1.6). The presence of a 
LIM domain is emerging as a hallmark of proteins that can associate with both 
the actin cytoskeleton and the transcriptional machinery (Johannessen et al., 
2006).  
 
 
Figure 1.6: Structure of FHL2. The LIM domain is a cysteine-rich motif with the consensus 
sequence CX2CX16–23HX2 CX2CX2CX16–21CX(C,H,D) that coordinately binds two zinc atoms and 
mediates protein–protein interactions. 
 
 
Northern blotting revealed that FHL2 is expressed at highest levels in heart and 
ovary, and at lower levels in skeletal muscle, prostate, testis, small intestine, 
and colon. Analysis of the expression pattern in normal human tissues revealed 
that FHL2 is expressed at high levels in the heart and skeletal muscle but also 
at lower levels in most other tissue, suggesting an important function in the 
specification of heart muscle cells (Genini et al., 1997). Therefore Chu et al. 
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(2000a), generated a mouse carrying a null mutation of the FHL2 gene, but 
failed to proof their hypothesis since FHL2 deficient mice are viable and 
maintain normal cardiac function both before and after acute mechanical stress 
induced by aortic constriction (Chu et al., 2000b).  
 
1.3.2 Function of FHL2 
FHL2 was shown by several other groups to be involved in various other cellular 
processes which can exert its function via two different mechanisms (Fig. 1.7). 
Stimulation of the Rho signaling pathway induces translocation of FHL2 to the 
nucleus (Morlon and Sassone-Corsi, 2003; Muller et al., 2002), where it acts as 
either transcription coactivator or corepressor in interaction with numerous 
transcription factors including the androgen receptor, AP1, CREB, PLZF, SKI, 
β-catenin, FOXO1, Runx2, Id2 and serum response factor (SRF; Chen et al., 
2003; Fimia et al., 2000; Gunther et al., 2005; Hamidouche et al., 2008; 
Labalette et al., 2004; Martin et al., 2002; Morlon and Sassone-Corsi, 2003; 
Muller et al., 2000; Paul et al., 2006; Philippar et al., 2004; Wei et al., 2003; 
Yang et al., 2005). SPP-induced FHL2 activation is mediated by Rho GTPases, 
but not by the GTPases Cdc42, Rac1 or Ras, and depends on Rho-kinase 
(Morlon and Sassone-Corsi, 2003; Muller et al., 2002). FHL2 may participate in 
a regulatory mechanism that coordinates cellular responses controlled by NF-
κB transcription factor (Stilo et al., 2002). All these data allude to FHL2 to play 
an important role in the modification of the transcriptional level of various genes.  
 
FHL2 has the capacity to interact, both in yeast and in mammalian cells, with 
itself, with the cytoplasmic domain of integrin α3A, α3B, α7A, and several β 
subunits, and with integrin-binding proteins (Wixler et al., 2000). This was 
investigated further by authors of Samson et al. (2004), who identified FHL2 
and FHL3 as novel α7β1 integrin-interacting proteins. Immunofluorescence 
studies with cells expressing full-length FHL proteins or their deletion mutants 
showed that FHL2 and FHL3 but not FHL1 colocalize with integrins at cell 
adhesion sites. Further, their recruitment to the membrane results from binding 
to either the alpha- or the beta-chain of the integrin receptor.  
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Figure 1.7: FHL2 plays a dual role within the cell. FHL2 can act as a co-activator of several 
transcription factors upon stimulation e.g. by Sphingosin-1-phosphate (S1P). Secondly, it binds 
to integrins which link the ECM and the actin cytoskeleton. 
 
 
1.3.3 FHL2 affiliates with actin associated proteins and structures 
FHL2 acts as an adaptor protein, regulating integrin trafficking, function or 
signaling pathways associated with cytoskeleton related genes, therefore may 
also play in migration. Co-localization of FHL2-(green fluorescent protein) GFP 
at focal adhesions was observed in C2C12, H9C2 myoblast as well as a 
nonmyogenic cell line, HepG2 cells. Moreover, FHL2 was observed along with 
F-actin and focal adhesion of C2C12 and H9C2 myotubes (Li et al., 2001). 
Cytoskeleton-associated proteins were shown to co-localize with FHL2 in cell 
lamellipodia (El Mourabit et al., 2004). FHL2 colocalizes to Grb7, which is an 
adaptor molecule and overexpression has been linked to enhanced cell 
migration and metastasis (Siamakpour-Reihani et al., 2009). Using 
mesenchymal stem cells from wt and FHL2-knockout mice, it was shown that 
inactivation of FHL2 leads to impaired assembly of ECM proteins on the cell 
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surface and to impaired bundling of focal adhesions (Park et al., 2008). A 
Disintegrin And Metalloproteinase (ADAM)-17 is a metalloprotease-disintegrin 
responsible for the ectodomain shedding of several transmembrane proteins, 
which colocalizes with FHL2 to the actin-based cytoskeleton (Canault et al., 
2006). 
 
Impaired cutaneous wound healing occurs in FHL2-deficient mice, which 
furthermore show collagen contraction and cell migration are severely impaired 
in FHL2-deficient cells. Consequently, the expression of alpha-smooth muscle 
actin is delayed in wounds of FHL2-deficient mice and the expression of 
p130Cas, which is essential for cell migration, is reduced in FHL2-deficient cells 
(Wixler et al., 2007). These results show impaired intestinal wound healing in 
FHL2-deficient mice is due to disturbed collagen III metabolism (Kirfel et al., 
2008). 
In a different study high levels of Lysine specific demethylase 1 (LSD1), nuclear 
expression of the FHL2 coactivator, high Gleason score and grade, and very 
strong staining of nuclear p53 correlate significantly with relapse during follow-
up. This suggests that LSD1 and nuclear FHL2 may serve as novel biomarkers 
predictive for prostate cancer with aggressive biology and point to a role of 
LSD1 and FHL2 in constitutive activation of AR-mediated growth signals (Kahl 
et al., 2006). 
 
1.4 Sphigosine-1-Phosphate Receptors (S1PR) 
FHL2 translocates into the nucleus upon binding of S1P and can act as a 
coactivator of transcription factors like AR or CREB/CREM in a cell type specific 
manner (Muller et al., 2002). S1P is a potent lysosphospholipid with a wide 
range of biological activities (Spiegel and Milstien, 2000) including regulation of 
cytoskeletal rearrangement and cell migration via the actions of five G-protein-
coupled receptors termed S1PR1-5, also known as endothelial differentiation 
gene (EDG), which mediate their functions through coupling of the receptor to 
heterotrimeric G-proteins (Takuwa et al., 2002). S1P is produced by platelets 
and red blood cells and circulates in the plasma at concentration of 10-7 M. S1P 
possess chemoattractive property for a variety of immune cells (Graeler and 
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Goetzl, 2002; Idzko et al., 2002), and has an impact of the egress of B and T 
cells from the LN and thymus (Matloubian et al., 2004). Furthermore, S1P is 
responsible for correct positioning of B cells and DC within the spleen (Cinamon 
et al., 2004; Czeloth et al., 2007).  
S1PR1 and S1PR3 usually promote cell migration via Gi pathways and Rac 
activation leading to lamellipodia formation (Paik et al., 2001), which 
observation could be extended to a variety of other cell types (Becker et al., 
2010; Gil et al., 2010; Liu et al., 2010). In contrast to S1PR2 which has a 
repellent effect on cell migration antagonizing Rac, stimulating G12/13 and Rho 
activation causing assembly of stress fibers (Fig. 1.8; (Arikawa et al., 2003; 
Okamoto et al., 2000; Sugimoto et al., 2003; Takashima et al., 2008). 
S1PR1-4 are expressed by a variety of immune cells, whereas expression of 
S1PR5 is mainly confined to cells of the central nervous system (Im et al., 
2000). S1P is the ligand for the five S1PRs, where S1PR1-4 are differentially 
expressed in T cells (Graeler and Goetzl, 2002) and bone marrow-derived 
dendritic cells (BMDC; Maeda et al., 2007). Depending on the maturation status 
of DC, they show a differential expression pattern of the S1PRs (Czeloth et al., 
2005; Maeda et al., 2007; Rathinasamy et al., 2010), which can either have an 
stimulatory or inhibitory regulation of migration (Sugimoto et al., 2003). This 
migratory effect is reflected by the expression pattern of S1PRs in DC causing a 
slower migratory behavior in their immature state leading to high migratory 
speed during maturation. Czeloth et al. (2005) showed that immature BMDC 
lack expression of S1PR1, and display only minor expression of S1PR3. These 
are highly upregulated after the maturation of BMDC, whereas expression of 
S1PR2 and 4 declines.   
 
Introduction 
 
22 
 
 
Figure 1.8: The coupling of the three S1P receptors to the Rho family GTPases. Both 
S1PR1 and S1PR3 mediate stimulation of Rac via Gi, leading to cell migration, whereas S1PR2 
mediates inhibition of Rac activity through an unknown mechanism, leading to inhibition of cell 
migration. S1PR3 and S1PR2 stimulate RhoA activity most likely via G12/13, however, stimulation 
of RhoA activity does not seem to be required for cell migration al least in CHO cells (Takuwa, 
2002). 
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1.5 Objective 
DCs are the first cells of defense against invading pathogens in an adaptive 
immune response. Therefore, DCs need to carry antigen, which they have 
taken up in the periphery, to the draining LN. Here, DCs present their antigen in 
MHC molecule to T cells. The communication between DC and T cell are very 
important in determining what kind of immune response is elicited, namely 
tolerance or immunity. Both can have detrimental effects for the organism: 
autoimmunity or no killing of the threatening pathogen. If a DC can reach the LN 
in a sufficient period of time, this is very critical to accomplish that task properly.  
FHL2 could play an important role in the mechanism of DC migration, since it is 
known to play in important role in fibroblast migration and subsequently wound 
healing and tumor formation. 
 
In this thesis the following questions will be addressed: 
1. What role does FHL2 play in DC migration? 
2. By which mechanism does FHL2 effect DC migration if at all. 
3. Does FHL2 play a role in other DC functions such as antigen uptake, 
antigen presentation and DC morphology? 
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2. Materials and Methods 
 
2.1 Materials 
2.1.1 Equipment 
Accurate Scales  PL-3001 (Mettler, Toledo, Greifensee, 
 Schweiz); BP211S 
(Sartorius;,Göttingen) 
Autoclave Tuttnauer 3870, Tuttnauer 5075 ELV  
(Biomedis, Gießen) 
Blotting Unit     XCell II Blot Module (Invitrogen,  
       Karslruhe) 
Bunsenburner    LABOGAZ 206 (Roth, Karlsruhe) 
Cell Separation   AutoMACS (Miltenyi, Bergisch 
Gladbach) 
Developer X-Omat 1000 Processor (Kodac, 
Rochester, USA) 
Electrophoresis Unit XCell SureLock Mini-Cell (Invitrogen, 
Karlsruhe) 
Electroporation Gene Pulser Xcell Electroporation 
System (Biorad, München) 
ELISA reader  ELX800 (BioTek Instruments, Bad 
Friedrichshall 
Flow Cytometer  FACS Canto (Becton Dickinson, 
Heidelberg) 
Fluorescence Microscope   IX71 (Olympus, Hamburg) 
Freezer (-20°C) 7081-598-03 (Liebherr, Biberach an der 
Riss) 
Freezer (-80°C)       HERAfreeze (Hereaus, Hanau) 
Ice machine     ZBE 70-35 (Ziegra, Isernhagen) 
Incubator  Cytoperm 2, BBD 6220 (Heraus, 
Hanau) 
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Laminar Flow Hood  HERAsafe, HERAguard (Heraeus, 
Hanau) 
Luminometer Centro LB 960 Berthold (VWR, 
Darmstadt) 
Magnetstirrer    RCT (IKA, Staufen) 
Microscope     Axiovert 40Cn (Zeiss, Oberkochen) 
Microwave     Microwave 800 (Severin, Sundern) 
Mini Centrifuge    Galaxy Mini (VWR, Darmstadt) 
Motorized rotor homogenizer  Fastprep (Sartorius, Göttingen) 
Orbital Shaker    VXR basic Vibrax (Ika, Staufen) 
pH Meter      Blueline pH 12 (Schott, Mainz) 
Power supply  Consort E835 (Rhys Scientific 
Ltd,,Lancashire, UK) 
Real-Time PCR System  7900HT (Applied Biosystems, 
Darmstadt)  
Refrigerator (+4°C)   7081-312-04 (Liebherr, Biberach an der 
Riss) 
Rocking Shaker           Duomax 1030 (Heidolph, Schwabach) 
Scale      440-45N (Kern, Balingen)  
Spectrophotometer  NanoDrop ND-1000  (PeqLab, 
Erlangen)  
Speed Rotator Intelli-Mixer RM-2 Elmi LV-1006 (Elmi, 
Riga, Latvia) 
Table Centrifuge     5417R (Eppendorf, Hamburg) 
Thermal cycler   MJ Research PTC-200 Peltier Thermal 
cycler (Biozym, Oldendorf) 
Thermomixer    Thermomixer (Eppendorf, Hamburg) 
Timelapse Microscopy   IX81 (Olympus, Hamburg)    
Vortex Genie 2 (Scientific Industries, New 
York, USA) 
Waterbath WB/OB7-45 WBU45 (Memmert, 
Schwabach) 
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2.1.2 Consumables 
384 Microreader plate  Thermo Fisher Scientific, 
Langenselbold   
Beaker 25ml, 100ml, 500ml  TGI, Ilmenau 
Chamber Slide2 well Permanox  Nalge Nunc International, New York, 
USA 
Cell Culture flasks
 
75cm2   Corning, Wiesbaden 
Cell strainer 40µm    Becton Dickinson, Heidelberg 
Centrifuge round bucket 500ml  Heraeus, Hanau  
Conical Tubes 15ml, 50ml   Greiner, Solingen. Corning; Wiesbaden 
Cover slips     Leica, Wetzlar 
Cover Slips, ∅13 mm    Assistent, Sondheim 
Electroporation Cuvette    Biorad, München 
Erlenmeyer flask 50ml, 100ml,   Schott, Mainz 
250ml, 500ml, 1l 
Falcon round-bottom tubes  Becton Dickinson, Heidelberg 
Filterflasks 1L 0.2µm   Corning, Wiesbaden   
Filter paper Whatmann 3MM Schleicher & Schuell, Dassel  
High performance     GE Healthcare, München 
Chemiluminiscence film  
Lysing Matrix D    Q-Biogen, Heidelberg 
Microplates flat bottom 96, 48 well Corning, Wiesbaden 
PCR tubes 0.2ml Greiner, Frickenhausen 
Microplates round-bottom 96 well Greiner, Frickenhausen 
Needle, 21G, 25G    Becton Dickinson, Heidelberg 
  
Neubauer Counting chamber  Roth, Karlsruhe 
Nitrocellulose membrane 0.2µm  BioRad, München 
Nunc Cryo tubes Thermo Fisher Scientific, 
Langenselbold   
Nylon Wool     Dunn Labortechnik, Asbach 
Petri dish, non tissue culture treated  Greiner, Frickenhausen 
10cm, 5cm    
Materials and Methods 
 
27 
Petri Dish 15cm    TPP, Trasadingen, Schweiz 
Pipette accu-jet    Brand, Wertheim 
Pipettes 0.2-2µl, 0.5-10µl, 2-20µl,  Eppendorf, Hamburg 
20-100µl, 30-200µl, 100-1000µl     
Snap cap microcentrifuge tube  Eppendorf, Hamburg 
500µl, 1ml, 2ml 
Strainer, metal, 100µm University Bonn, Department 
„Feinmechanik“ 
Stripes Serological Pipets Corning, Wiesbaden 
Syringe 1ml, 5ml, 10ml   Becton Dickinson, Heidelberg  
Threaded bottles100ml, 250ml,   Schott, Mainz 
500ml, 1l, 2l  
Transwell 5µm, 24 well   Corning, Wiesbaden 
Ultrapure water system    Reinstwassersysteme, Leverkusen. 
NANOpure Diamond, Barnstead  
µ-Slide Chemotaxis    IBIDI, München 
 
2.1.3 Chemicals (liquid) 
Acetic acid (CH3COOH)    Merck, Darmstadt 
Acetone (C3H6O)    Merck, Darmstadt 
Bradford reagent    BioRad, München 
β-mercaptoethanol (C2H6OS)  Merck, Darmstadt 
Citric acid (C6H8O7)    Merck, Darmstadt 
Dimethyl sulfoxide (C2H6OS)  Sigma, Steinheim 
Ethanol (C2H6O)    Merck, Darmstadt 
Glycerol 87% (C3H8O3)   Merck, Darmstadt 
Hydrochloric acid (HCl)   Merck, Darmstadt   
Hydrogen peroxide (H2O2)   Roth, Karlsruhe 
Methanol (CH4O)    KMF, Lohmar 
Tween 20 (C58H114O26)   KMF, Lohmar 
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2.1.4 Chemicals (solid) 
Agarose (C12H18O9 )    Biozym, Oldendorf   
  
2,2'-azino-bis(3-ethylbenzo-   Sigma, Steinheim 
thiazoline-6-sulphonic acid)  
(C18H18N4O6S4)       
Bovine serum albumin   Biolabs, SIGMA 
Bromophenol blue (C19H10Br4O5S) Fluca, Steinheim 
Deoxycholic acid (C24H40O4)  Roth, Karkruhe 
Ethylenediaminetetraacetic acid  Merck, Darmstadt 
(C10H16N2O8 ) 
Gelatine     Sigma, Steinheim 
Milk powder     Merck, Darmstadt 
Nonidet P-40    Roth, Karlruhe 
Saponin     Merck, Darmstadt 
Sodiumazid (NaN3)   Sigma, Steinheim 
Sodium chloride (NaCl)   Merck, Darmstadt 
Sodium dodecyl sulfate    Roche, Berlin 
(NaC12H25SO4) 
Sodium hydrogen phosphate  Merck, Darmstadt 
(Na2HPO4) 
Sodium hydroxide (NaOH)   Merck, Darmstadt 
Tris(hydroxymethyl)aminomethane  Merck, Darmstadt 
(C4H11NO3)     
Triton X-100 (C14H22O(C2H4O)n)  Merck, Darmstadt 
Paraformaldehyde    Fluca, Steinheim 
(OH(CH2O)nH (n = 8 - 100))    
Xylencyanol (C25H27N2NaO6S2)   Roth, Karlsruhe 
 
2.1.5 Reagents 
5x First strand Buffer   Invitrogen, Karlsruhe 
10x PCR Rxn Buffer   Invitrogen, Karlsruhe 
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100bp Molecular Ruler   BioRad, München 
10x RT Buffer    Invitrogen, Karlsruhe 
Affinity purified mouse CCL19-Fc  eBioscience, San Diego, USA 
fusion protein   
AllStars negative control siRNA  Qiagen, Hilden 
Antibody diluent Dako, Hamburg 
Calibrate beads Becton Dickenson, Heidelberg 
Dithiothreitol     Invitrogen, Karlsruhe 
dNTP Mix     Invitrogen, Karlsruhe 
Ethidium bromide solution   Fluca, Steinheim 
LPS      Sigma, Steinheim 
Magnesium chloride   Invitrogen, Karlsruhe 
Mini Complete    Roche, Berlin 
Mounting medium    Dako, Hamburg 
Normal mouse serum   Sigma, Steinheim 
Normal rat serum    Sigma, Steinheim 
Oligo(dt)-Primer12-15   Invitrogen, Karlsruhe 
Prostaglandin E2    Sigma, Steinheim 
Protein G PLUS-Agarose    Santa Cruz Biotechnology, Heidelberg 
Proteinase K solution   Qiagen, Hilden 
PureCol Collagen Sigma, Steinheim  
RLT Buffer     Qiagen, Hilden 
RNase-free water    Qiagen, Hilden 
Rnase OUT     Invitrogen, Karlsruhe 
S1PR1 siRNA    Qiagen, Hilden 
SuperScript III Reverse Transcriptase  Invitrogen, Karlsruhe 
Taq DNA polymerase   Invitrogen, Karlsruhe   
Protein G PLUS-Agarose    Santa Cruz Biotechnology, Heidelberg 
 
2.1.6 Antibody coated beads  
CD4 (L3T4) MicroBeads   Miltenyi Biotec, Bergisch Gladbach 
CD8 (Ly-2) MicroBeads   Miltenyi Biotec, Bergisch Gladbach 
CD11c MicroBeads    Miltenyi Biotec; Bergisch Gladbach 
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2.1.7 Fluorochrome labeled ligands  
DextranFITC     Sigma, Steinheim 
OVAAlexa647     Invitrogen, Karlsruhe 
PhalloidinAlexa488    Invitrogen, Karlsruhe  
PhalloidinAlexa546    Invitrogen, Karlsruhe 
PhalloidinAlexa647    Invitrogen, Karlsruhe 
 
2.1.8 Fluorochromes  
Carboxyfluorescein succinimidyl   Molecular Probes, Karlsruhe 
ester (C25H15NO9)       
4',6-diamidino-2-phenylindole  Invitrogen, Karlruhe 
SNARF-1 carboxylic acid, acetate,  Molecular Probes, Karslruhe 
succicimidyl ester   
 
2.1.9 Enzymes  
Collagenase A    Sigma, Steinheim 
 
2.1.10  Proteins  
Ovalbumin     Serva, Heidelberg 
 
2.1.11 Inhibitors  
Brefeldin A     eBioscience, San Diego, USA 
CCG-1432     Cayman Chemical, Tallinn, Estonia 
Fasudil hydrochloride  Tocris Bioscience, Bristol, United 
Kingdom 
Monensin     eBioscience, San Diego, USA 
SEW8271     Cayman Chemical, Tallinn, Estonia 
S1P      Sigma, Steinheim 
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Y27632     Merck, Darmstadt 
 
2.1.12 Cytokines and Chemokines 
Recombinant IL-2    Peprotech, Hamburg  
Recombinant Mouse MIP-3/CCL19 R&D Systems, Wiesbaden-Nordenstadt 
Recombinant murine TNF-α  Peprotech, Hamburg 
 
2.1.13 Cell culture supplies 
ACK lysis buffer    Lonza, Köln 
Fetal calf serum    PAA, Cölbe 
G418      PAA, Cölbe 
IMDM medium    PAA, Cölbe 
L-Glutamine     Gibco, Karlsruhe 
Optimem     Invitrogen, Karlsruhe 
Penicillin/Streptomycin   PAA, Cölbe 
PBS      PAA, Cölbe 
RPMI Medium    Gibco, Karlsruhe 
Trypan blue     Sigma, Steinheim 
Trypsin-EDTA    PAA, Cölbe 
 
2.1.14 Western Blot supplies 
MOPS SDS Running Buffer (20x) Invitrogen, Karlsruhe 
Novex® Sharp Pre-stained Protein  Invitrogen, Karlsruhe 
Standard   
NuPAGE 4-12% Bis-Tris Gel   Invitrogen, Karlsruhe 
(1.5mmx15 well)   
NuPAGE LDS Sample Buffer (4x) Invitrogen, Karlsruhe 
NuPAGE Transfer Buffer (20x)  Invitrogen, Karlsruhe 
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2.1.15 Oligonucleotides       
All primers are HPLC purified and purchased ready lyophilized at a 
concentration of 10µM. They were 1:10 diluted in ddH20. SIGMA-Proligo, 
Steinheim. 
 
Table 2.1: The list of primers used for the PCRs. 
Name Sequence 5’ – 3’ 
Myco C GGGAGCAAACAGGATTAGATACCCT 
Myco D TGCACCATCTGTCACTCTGTTAACCTC 
FHL2 Exon1 F TTGCTGAAAGACAGGTGTCAGC 
FHL2 Exon1 R TTGCAGTCGCAGCCGATGGG 
b-actin F CTACGTCGCCCTGGACTTCGAGC 
b-actin R GATGGAGCCGCCGATCCACACGG 
18s F ACAGCCAGGTTCTGGCCAACGG 
18s R TGACCGCGGACACGAAGGCCC 
S1PR1 F TCTCTGACTATGGGAACTATG 
S1PR1 R CCAGGATGAGGGAGATGA 
S1PR2 F CCTTAACTCACTGCTCAATCC 
S1PR2 R GCTGGAAGATAGGACAGACAG 
S1PR3 F ACAAGGTCCGGGTGCTGA 
S1PR3 R GTAATGTTC CCGGAGAGTGTC 
S1PR4 F GCTATGCCCATTGTCCAGTAG 
S1PR4 R GGACCAGGTACTGATGTTCATG 
 
2.1.16 Antibodies 
Table 2.2: Antibodies used in Western blot or for Immunoprecipitation. 
Antigen Isotype Clone Remark Company 
b-actin IgG, mouse AC-15 monoclonal Sigma 
FHL2 IgG, rabbit  polyclonal self-produced 
FHL2 IgG1, mouse F4B2-B11 monoclonal Novus Bilogicals 
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Table 2.3: Antibodies used for flow cytometry. 
Antigen Isotype Clone Remark Company 
TNF-α IgG1 k, rat MP6-XT22   eBioscience 
IL-12 p35 IgG2a k, rat 4D10p35  eBioscience 
CD11c IgG, hamster N418 Integrin αX 
chain eBioscience 
CD16/32 IgG2b k, rat 2.4G2 Fc RII/III self produced 
MHCI IgG2a κ, rat AF6-88.5 H-2Kb eBioscience 
MHCII IgG2b κ, rat M5/114.15.2 I-A b eBioscience 
CD40 IgG2a κ, rat HM40-3  eBioscience 
CD80 IgG, hamster 16-10A1 B7-1 eBioscience 
CD86 IgG2a κ, rat GL1 B7-2 eBioscience 
 
Table 2.4: Antibodies used for ELISA. 
Antigen Isotype Clone Remark Company 
IL-2 IgG2b, rat JES6 1A12 pure eBioscience 
IL-2 IgG2b, rat JES6 5H4 biotinylated eBioscience 
 
Table 2.5: Functional antibody used for in vivo injection. 
Antigen Isotype Clone Remark Company 
NK 1.1 IgG2a, mouse PK136 pure self produced 
 
 
2.1.17 Secondary antibodies 
Anti-mouse HRP     Sigma, Steinheim 
Anti-rabbit HRP     Invitrogen, Karslruhe 
Strepavidin PerCpcy5.5    eBioscience, San Diego, USA 
Anti-Human IgG (Fc gamma-specific)   eBioscience, San Diego, USA 
Anti-mouse IgG-Peroxidase antibody  Sigma, Steinheim 
anti-mouseTexas Red     Southern Biotech, Eching 
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2.1.18 Kits 
Amersham ECL Western blotting  GE Healthcare, München 
Analysis System  
Cell Proliferation Kit I (MTT)  Roche, Berlin 
mirVana miRNA Isolation   Ambion, Darmstadt 
NucleoSpin RNAII     Macherey&Nagel, Düren 
QuantiFast SYBR Green PCR Kit Qiagen, Hilden  
Rac1 ELISA Kit    Cytoskeleton, Offenbach 
RNeasy Midi Kit    Qiagen, Hilden 
RNeasy Mini Kit    Qiagen, Hilden 
 
2.1.19 Media, Solutions and Buffer 
1xTBS-T    10xTBS was diluted 1:10 in ddH2O 
0.1% Tween 
 
10xTBS   1l ddH2O 
200mM Tris  
1.4M NaCl 
adjusted to pH 7.6 with HCl 
 
50xTAE Buffer  1l ddH2O 
1M Tris  
17.51% acetic acid 
0.5M EDTA  
 
Freezing Medium  FCS 
    20% DMSO  
    
ABTS buffer   17.89g citric acid, monohydrate  
1000ml H
2
O  
pH 4.35  
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Acetic acid 100mM  50ml ddH20  
286µl acetic acid  
 
BMDC medium   500ml IMDM medium  
8% heat inactivated FCS 
2µM β-ME 
1x P/S 
2mM L-Glutamine. 
 
BMDC medium/BSA 500ml IMDM medium  
8% heat inactivated FCS 
2µM β-ME 
1x P/S 
2mM L-Glutamine 
2.5g BSA 
 
Coating buffer  0.1M Sodium hydrogen phosphate in ddH20  
 
EDTA 0.5M   50ml ddH20 
18.6g EDTA  
adjusted to pH8 with 5M NaOH 
 
FACS buffer    500ml 1xPBS 
0.1% Na azid 
1% BSA. 
 
Freezing Medium  FCS 
    20% DMSO  
 
Laemmli buffer  20% Glycerol, 1.5M Tris-HCl 
    0.01g bromphenolblue 
 
Loading dye   50ml ddH2O 
0.5ml of 1M Tris (pH8) 
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5µl of 0.5M EDTA (pH8) 
28.74ml of 87% glycerol 
0.025g Bromphenol blue 
0.025g Xylencyanol  
 
MACS buffer   500ml 1xPBS  
0.1% Na azid 
1% BSA 
2mM EDTA 
 
RIPA buffer   in ddH2O 
    150mM NaCl 
    0.5% Deoxycholic acid 
    1% NP-40  
    0.1% SDS  
    50mM Tris  
1 tablet Mini Complete was added to 10ml RIPA 
buffer   
 
T cell medium  RPMI medium  
8% FCS 
2µM β-ME 
1x P/S 
2mM L-Glutamine. 
 
2.1.20 Software 
Cell^R Imagingsystem  Olympus, Hamburg 
FlowJo    FlowJo, Ashland, USA 
SDS2.2    Applied Biosystems, Darmstadt 
Track-it software   Olympus, Hamburg 
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2.1.21 Cell lines 
Ag8653  GMCSF producing hybridoma cell line 
 
 
2.1.22  Mouse lines 
All mice were on the C57BL/6 background. Experimental animals were bred 
under specific pathogen free (SPF) conditions according to the FELASA 
guidelines in the central animal facility “Haus für Experimentelle Therapie” 
(HET) at the University Hospital Bonn. For all experiments mice between 6-20 
weeks of age were used in accordance with local animal experimentation 
guidelines.  
 
C57Bl/6 Inbreed line with MHC class I Haplotype H2K b 
FHL2-/-  (Kon et al, 2001) 
OT-I IxRag CD8 T cell transgene mouseline, H2KbSIINFEKL-restricted 
Vα2Vβ5 
T cell receptor (Hogquist et al., 1994). 
OT-II  CD4 T cell transgene mouseline, I-Ab  
 
 
2.2 Methods 
 
2.2.1 Cell Culture 
2.2.1.1 Primary cell isolation 
All mice used for organ removal to receive primary cells were between 6 and 20 
weeks old. Prior to organ removal mice were sacrificed by CO2 mediated 
asphyxiation. Body Surfaces were cleaned with 70% Ethanol and body cavity 
was opened under semi sterile conditions with forceps and scissors. 
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2.2.1.2 Production of GMCSF 
The myeloma cell line AG8653 produces murine recombinant GMCSF under 
neomycin (G418) selection, which supernatant was added to the BMDC culture 
to turn bone marrow precursor cells into DC. Cells were expanded in IMDM 
medium under G418 selection with a final concentration of 1mg/ml for several 
days until the cells were about 80 to 90% confluent. Medium was aspirated, the 
cells were washed with PBS and detached from the plastic surface by Trypsin-
EDTA at 37°C for 5min. Reaction was stopped by adding equal volume of 
medium and centrifuged at 1500rpm for 5min. Cells were washed three times 
with PBS to remove G418  and in the in the end resuspended in IMDM medium 
and counted. 5x105 cells were plated on 15cm dishes in 20ml volume of IMDM 
medium for four days. The supernatant was collected in centrifuge buckets for 
centrifugation 1500rpm for 10min and filtered through 0.2µm pore size to 
exclude cells and stored at -20°C. 
 
2.2.1.3 Determination of cell number 
The harvested cell suspension was diluted with Trypan Blue, and 10µl were 
applied to the edge of the hemocytometer. It consists of four squares, each 
made up of another 16 smaller squares. All four big squares were counted, 
excluding dead cells characterized by a deep blue color and the concentration 
of the cell suspension was calculated by the help of following formula. In order 
to get an accurate number, the number of cells in the small square should be 
between 30 to 200. 
 
Number of cells/ml = Number of counted cells/4 * dilution factor * 10,000 
 
2.2.1.4 Generation of bone marrow derived dendritic cells 
Femur and tibia from FHL2-/- and wt mice were removed, and fur and muscle 
tissue carefully subducted with sterile forceps. The end on the bones were cut 
open and flushed through with IMDM medium, centrifuged at 1500rpm for 5min, 
resuspended in fresh medium and counted. 5x106 cells were cultured in 10cm 
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untreated Petri dishes in IMDM medium in a final volume of 10ml supplemented 
with 30% GMCSF containing supernatant prepared as described in 2.2.1.2. 
After four days, medium including BMDCs was transferred into a conical tube, 
washed twice with 3ml PBS and detached with 1mM EDTA/PBS including the 
cells in the medium. 3x106 cells were plated under the same conditions as 
described before for further three days. This yielded a 60 to 80% pure CD11c 
positive BMDC culture as determined by flow cytometry.  
Optionally on day seven, maturation was induced with either 100ng/ml LPS for 
24 hours or 30ng/ml TNF-α for 48 hours depending on the setup of the 
experiment. Incubation with several inhibitors was done as described in Results. 
 
2.2.2 Molecular Biological methods 
2.2.2.1 Mycoplasma PCR 
Contamination of cells with mycoplasma can lead to cell death or it could 
influence the phenotype of the cells, which could change the outcome of 
experiments. Therefore cells were checked for mycoplasma contamination on a 
regular basis by PCR with primers covering most strains. Medium of cells was 
not changed at least for two days. 200µl of medium was taken and heated up 
for 10min at 95°C. Every PCR reaction was done simultaneously with two 
positive control samples (Table 2.6). 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and Methods 
 
40 
Table 2.6: The recipe of the Mycoplasma PCR and the PCR program. 
Reagents Concentration Volume µl 
ddH20  16.8 
PCR Rxn Buffer 10x 2.5 
MgCl2  50mM 1 
dNTPs 10mM 10mM 0.5 
Primer Myco C 1µM 1 
Primer Myco D 1µM 1 
Taq DNA polymerase 5U/µl 0.2 
DNA sample  2 
   
Program: Temperature °C Time 
 94 3min 
 94 30s 
 55 30s 
 72 45s 
 33 cycles  
 
2.2.2.2 Isolation of total RNA from tissue 
In order to check for FHL2 expression in several organs RNA was isolated from 
lung, colon, muscle and heart tissue with the “RNeasy Midi” kit according to 
manufacturers’ instruction. 
100mg of tissue were taken up in 1ml RLT Buffer provided by the manufacturer 
supplemented with 10% β-ME and placed in a “Lysing Matrix D” vessel and 
disrupted with a motorized rotor homogenizer for 60s. Heart tissue was 
incubated in 20mg/ml Proteinase K solution dissolved in ddH20 at 55°C for 
20min to destroy contractile proteins, connective tissue and collagen. The 
concentration of RNA was determined with “Nano Drop”.  
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2.2.2.3 Isolation of total RNA from cell culture 
Total RNA was isolated out of seven to days BMDC using either the ‘RNeasy 
Mini Kit’ or ‘NucleoSpin® RNA II’ following manufacturers’ instruction. For every 
experiment the same number of cells was loaded on the spin columns and 
eluted in RNAse free water. The concentration of RNA was determined with 
‘Nano Drop’.  
 
2.2.2.4 RT-PCR 
The conversion of RNA isolated from BMDC cell culture and tissues into cDNA 
was performed with ‘SuperScript™ III Reverse Transcriptase’. For every 
experiment the same amount of RNA was used varying between 200ng to 1µg 
depending on the yield of RNA from each sample in a final volume of 11µl of 
RNase free water. To each reaction 1µl of 10mM dNTP mix (10mM each dATP, 
dGTP, dCTP and dTTP at neutral pH) and 1µl of 50mM Oligo(dt)12-18 was added 
to a nuclease-free microcentrifuge tube, and heated for 5min at 65°C and 
cooled down for a minute on ice. The following components were added to each 
mixture: 4µl of 5X First-Strand Buffer, 1µl 0.1M DTT, 1µl RNaseOUT™ 
Recombinant RNase Inhibitor (40U/µl), and 1µl of SuperScript™ III RT 
(200U/µl); and incubated in a thermocycler for 60min at 60°C and inactivated at 
70°C for 15min. The final volume of 20µl was further diluted 1:10 or sometimes 
1:20 before used in Real Time PCR. 
 
2.2.2.5 Semi-quantitative RT-PCR 
40ng of target cDNA was added to a thin-walled tube and mixed together with 
10x PCR Rxn Buffer, 2mM MgCl2, 0.2mM dNTP mix and 1U of Taq DNA 
Polymerase. 40nM of primers were used for the amplification of Exon1 of FHL2 
with FHL2 Exon1 F and R primer. As a positive control β-actin is amplified as 
well, since it is abundantly and ubiquitously expressed in tissue.  
The sample is heated to 94°C to cause denaturation, which is followed by 
rapidly cooling to 60°C allowing the primers to anneal. During elongation the 
temperature is raised to 72°C. This course was repeated 33 times. 
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2.2.2.6 Gel Electrophoresis  
To prepare a 1.5% concentrated agarose gel, 2.25g agarose was weighed and 
mixed with 150ml of 1x TAE Buffer, heated in a microwave until it is dissolved. 
To visualize DNA products, 20µl of ethidium bromide was added which 
intercalates into double stranded DNA. It was cooled down for a short period of 
time, and then cast in the form. 12.5µL of PCR-product together with 2.55µL 
brom phenol blue loading dye is loaded on 1.5% agarose gel, which was run for 
30 min at 150V. The sizes of fragments were compared to 100 bp-ladder 
creating 10 bands ranging from 100 to 1000 bp.  
 
2.2.2.7 Transfection of BMDC with siRNA 
A total of 4x106 in 200µl Optimem medium day 7 BMDCs were put in a cuvette 
together with 5µg S1PR1 siRNA, as well as with 5µg AllStars Negative Control 
siRNA. The cuvette was placed in ‘Gene Pulser Xcell Electroporation System’ to 
be electroporated with a square wave protocol (300V, 6ms), and plated in 5cm 
plate dish. 48hrs later, transfected BMDCs were allowed to migrate in a 
Transwell as described in 2.2.4.2, and in parallel RNA was isolated and 
converted to cDNA to assess the expression of S1PR1 with qRT-PCR as 
described in detail in previous and following sections. 
 
2.2.2.8 Quantitative Real-Time PCR 
In order to monitor expression levels of RNA in a quantitative way, we used the 
‘QuantiTect SYBR Green PCR Kit’. SYBR Green is an asymmetrical cyanine 
dye, which preferentially binds to double stranded DNA and the resulting DNA-
dye-complex absorbs blue light (λmax = 488nm) and emits green light (λmax = 
522nm). 5µl of ‘2x QuantiFast SYBR Green PCR Master Mix’ was mixed with 
1µl cDNA converted by ‘SuperScript™ III Reverse Transcriptase’, and 0.5µl 
each forward and reverse primer each having a final concentration of 50nM and 
filled up with RNAse free water to get a final volume of 10µl. Every sample was 
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referenced to a housekeeping gene i.e. 18s. Every sample reaction was set up 
in triplicates in a 384 well format, and run on the ‘7900 HT ABI Prism’ with the 
following course of program: 50°C for 2min, 95°C for 10min, 95°C for 15s and 
60°C for 1min and the last to steps repeated 40 times. The data were analyzed 
with SDS2.2. 
 
2.2.3 Protein Biochemical methods 
2.2.3.1 Sample Preparation for western blot 
Heart and skeletal muscle tissue was squeezed through a sieve to obtain single 
cells. These cells and BMDC harvested on day 7 were washed with PBS. The 
cells stayed on ice in 100µl of RIPA Buffer and were vortexed in between in 
order to release proteins. After 30 to 45min the samples were centrifuged for 
15min at 15,000rpm to gain the supernatant containing proteins, which were 
stored in a freezer at -20°C. 
 
2.2.3.2 Protein determination by Bradford Assay 
The Bradford assay determines protein concentration based on a shift of 
absorbance when the former red Bradford reagent is stabilized into Coomassie 
blue by the binding of protein. The concentration of each sample can be 
calculated from a calibration curve prepared from the Bradford reagent bound to 
BSA ranging in concentration from 0 to 10µg. Here, the varying amounts of BSA 
was pipetted to sterile water in a total volume of 80µl of ddH2O in 96 well flat 
bottom ELISA plate and 20µl of Bradford reagent was added to BSA. For the 
determination of the sample concentration 1µl was added to 20µl Bradford 
reagent and 79µl sterile water. The amount of the complex formed was read in 
an ELISA reader at 595nm. 
 
2.2.3.4 SDS-PAGE 
SDS-PAGE is a technique used to separate proteins according to their 
electrophoretic mobility. 20µg of protein were mixed with ‘NuPAGE LDS Sample 
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Buffer (4x)’ in a final volume of 20µl filled up with PBS and denatured for 5min 
at 95°C. Proteins were loaded on ‘NuPAGE 4-12% Bis-Tris Gel (1.5mmx15 
well)’, which is placed in the ‘XCell SureLock Mini-Cell’ device filled with 1x 
MOPS SDS Running Buffer. The size of the proteins is compared to the 
‘Novex® Sharp Pre-stained Protein Standard’ consisting of 12 pre-stained 
protein bands in the range of 3.5 to 260kDa. Proteins were separated for 1hr at 
170V. 
 
2.2.3.5 Western Blot 
The separated proteins were transferred from the gel to a Nitrocellulose 
membrane by the help of the ‘XCell II Blot Module’ containing ‘NuPAGE 
Transfer Buffer’ at 30V for 1hr. The membrane was washed with TBS-T. 
 
2.2.3.6 Detection of FHL2 and β-actin 
The membrane was blocked overnight at 4°C in 0.1%MP/TBS-T. Subsequently, 
the membrane was incubated in 0.1%MP/TBS-T with 50ng/ml monoclonal anti-
FHL2 antibody or 200ng/ml monoclonal anti-β-Actin antibody for 1 hour at RT. 
After washing the membrane five times for 5min in 0.1%MP/TBS-T, the 
membrane was exposed to 3.25µg/ml anti-mouse IgG (Fab specific)-Peroxidase 
antibody for 30min at RT. The membrane was washed as described before, 
which was followed by visualization with the ECL Western blotting detection 
reagents and analysis system.  
 
2.2.3.7 Immunoprecipitation  
For immunoprecipitation (IP), 1mg of total protein prepared as described in 
2.2.3.1 of total wt and FHL2-/- BMDC lysates were incubated with 4µg 
polyclonal Ab directed against FHL2 (a kind gift by R. Schüle, Freiburg, 
Germany) in total volume of 250µl. The complexes were precipitated using 
‘protein G PLUS-Agarose’ at 4°C overnight. Prior protein G PLUS-agarose was 
precleared with double volume of RIPA buffer for 1h at 4°C in a Speed shaker 
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and centrifuged for 5min at 2500rpm. At the next day the complexes were 
washed three times with RIPA buffer for 5min at 2,500rpm at 4°C, and 
subsequently boiled in 20µl Laemmli buffer for 10min at 95°C, which was 
loaded on “NuPAGE 4-12% Bis-Tris Gel (1.5mmx15 well)” to be analyzed for 
FHL2 expression as described previously in section 2.2.3.5. 
 
2.2.3.8 Immunofluorescence 
 The morphology of 2x105 BMDC was studied when staining for actin 
cytoskeleton and nucleus on collagen coated cover slips with a diameter of 
13mm put in a 24 well plate. Therefore, 3mg/ml Collagen diluted 1:100 in 
100mM acetic acid was polymerized for 30min at 37°C and washed twice with 
ddH20.  
BMDC were left to adhere for one hour at 37°C. BMDC were fixed with 4% PFA 
for 15min on ice, and subsequently permeabilized on ice for one hour in 
5%MP/0.1%Triton/1%serum/PBS. Actin filaments were stained with 0.4U/ml 
phalloidinAlexa546 in 0.1%Triton/1%mouse serum/PBS for 30min at 37°C. The 
nucleus was stained with DAPI in PBS for 15min at 37°C. Finally, the cover 
slips were put on a microscopic slide with mounting medium preserving the 
fluorescence. Stained BMDC were viewed with Olympus IX71. 
When stained for FHL2 another protocol was followed. Wt BMDCs were also 
plated on Collagen coated surfaces as described before. Cells were fixed for 
15min on ice with PFA, and subsequently permeabilzed for 5min at room 
temperature in 0.2% Triton/PBS. In between all incubation steps it was washed 
at least twice with PBS for 5min. Cells were blocked for 2hrs in 
0.2%gelatine/PBS. Actin filaments were stained with 1U/ml phalloidinAlexa488, 
and simultaneously FHL2 with monoclonal anti-FHL2 antibody diluted 1:50 in 
Antibody Diluent for 2hrs at RT. Secondary antibody anti-mouseTexas Red directed 
against FHL2 was, and simultaneously the nucleus was stained with DAPI in 
diluted 1:1,000 in Antibody Diluent for 2hrs at RT. Finally, the cover slips were 
put on a microscopic slide with mounting medium preserving the fluorescence. 
Stained BMDC were viewed with Olympus IX71. 
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2.2.4 Migration assays 
2.2.4.1 Timelapse-video microscopy 
Prior to use µSlides were coated with Collagen for 30min at 37°C, which was 
diluted in 100mM acetic acid 1:100 to receive a final concentration of 300µg/ml, 
and afterwards the slides were washed twice with PBS. 1x105 BMDC in IMDM 
Medium were allowed to adhere to µSildes for 45 min at 37°C. Timelapse 
images were taken every 15s for 30min to determine the migratory speed 
without chemokine stimulation using a Cell^R Imagingsystem. After that a 
CCL19 gradient was set up with 40µl of 20µg/ml chemokine and the cells were 
imaged for a further 60min at 37°C. 
Migratory speed, directionality and migratory distance were determined using 
the Track-it software. 
 
2.2.4.2 Transwell Assay 
2.5x105 unstimulated, LPS and TNF-α stimulated BMDC in 100µl BSA/IMDM 
medium were added to the top chamber of the insert of the Transwell with a 
pore size of 5µm. The bottom chamber was filled with 600µl IMDM/BSA 
medium containing 10ng/ml CCL19. Cells were allowed to transmigrate for 3hrs 
at 37°C, harvested from the bottom chamber using 2mM EDTA/PBS, and 
stained for CD11c positive cells. In order to quantify the number of cells arrived 
in the bottom chamber 5,000 Calibrate beads were added to each sample 
during acquisition with FACS Canto.  
 
2.2.4.3 In vivo migration 
107/ml TNF-α matured or nonmatured BMDC were incubated with either 1µM 
CFSE or 10µM SNARF for 10min at 37°C and reaction was stopped with 10% 
FCS. FHL2-/- and wt BMDC labeled with CFSE respectively SNARF were 
mixed in equal proportions and 2x106 BMDC in 20µl PBS were injected to the 
footpad of wt mice. To exclude any dye specific inhibition a dye switch was 
conducted. Twenty six hours later the cells were recovered from popliteal LN, 
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which was minced with the stamp of a syringe and squeezed through a cell 
strainer to get single cell suspensions. The sample were stained with a CD11c-
pacific Blue conjugated mAB for 30min on ice in the dark and analyzed on 
FACS Canto. In addition the mixture injected into the footpad was acquired to 
check that an equal proportion was injected and minor changes were 
considered for the calculation.  
 
2.2.4.4 Determination of survival by MTT Assay 
The assay is designed for the spectro-photometric quantification of cell growth 
and viability based on the cleavage of the yellow tetrazolium salt MTT labeling 
reagent (1x), to purple formazan crystals by metabolic active cells involving the 
pyridine nucleotide cofactors NADH and NADPH. Day 7 wt and FHL2-/- BMDC 
were harvested and 2x105 BMDC were plated in 100µl in 96 well plate 
flatbottom set up as a six fold determination and left to adhere for one hour 
which represent the reference group. At the same time BMDC adhered for 
24hrs and the same procedure described in the following was applied for both 
days. BMDC were incubated for 4hrs with 10µl of MTT labeling reagent (final 
concentration 0.5mg/ml) per well and 100µl Solubilization solution (10% SDS in 
0.01 M HCl) is added to each well and let stand overnight in the incubator until 
complete solubilization of the purple formazan crystals occurs. The 
spectrophotometrical absorbance of the samples was measured using an 
ELISA reader at 600nm and reference wavelength at 650nm. 
 
2.2.5 Flow cytometry 
2.2.5.1 Staining of surface markers 
Cells were washed in FACS buffer and incubated with 10µg/ml anti-Fc RII/III 
mAb to block unspecific binding of the following Ab reagents. PE-labeled mAbs 
(used at 5–20 µg/ml) against MHC class I, MHCII, and biotinylated mABs 
against CD40, CD80 and CD86 were used. Furthermore all cells were labeled 
with CD11c APC conjugated mAB. Isotype controls included purified rat IgG2a, 
either PE labeled or biotinylated IgG. After incubation with mAbs for 20 min at 
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4°C and washing in FACS buffer, cells coupled to a biotinylated mAB, were 
incubated with Strepavidin conjugated PerCPCy5.5. FACS analysis was 
performed on a flow cytometer FACS Canto. FACS data were analyzed using 
FlowJo software. 
 
2.2.5.2 Intracellular cytokine staining 
2x105 immature and LPS matured BMDCs plated in a 96 well flat bottom in 
100µl IMDM Medium were incubated in the presence of Monensin and Brefeldin 
A, which were diluted 1:1000, for 5h. After surface staining with CD11c PE, 
BMDCs were fixed with 4% PFA for 10min on ice, permeabilized with 0.5% 
saponin/FACS buffer for 15min on ice, and stained with Abs against IL-12 and 
TNF-α conjugated to Alexa647. 
 
2.2.5.3 Expression of CCR7 
CCR7 on BMDC were detected with the purified mouse CCL19-Fc fusion 
protein as described in (Hargreaves et al., 2001). Briefly, 0.1µg of CCL19-Fc 
fusion protein in 10µl FACS buffer per sample was incubated for 30min on ice. 
1µg of PE goat anti-human IgG Fcγ Fragment, which was pre absorbed in 2% 
mouse and rat serum in a ratio 1:1, and 50ng CD11c APC were added to the 
sample to a final volume of 50µl FACS buffer, and incubated for 15min on ice. 
FACS analysis was performed on a flow cytometer FACS Canto. FACS data 
were analyzed using FlowJo software. 
 
2.2.5.4 Quantification of F-actin by flow cytometry 
On day seven the medium of wt and FHL2-/- BMDC was substituted by medium 
containing 0.5% FCS for two days. Under both conditions the maturation was 
induced by TNF-α. BMDC were harvested and the surface was stained with 
CD11c-PE conjugated mAB, and afterwards stained intracellularly by fixing with 
4% PFA for 10min on ice and permeabilizing with 0.5% Saponin/FACS buffer 
for 15min on ice. F-actin was stained with 0.2U/ml phalloidin conjugated to 
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Alexa647 in 50µl FACS Buffer for 30min on ice, and analyzed by flow 
cytometry. All samples were set up in triplicates. 
 
2.2.6 Rac1 Activation Assay 
The activity of Rac1 was investigated with an ELISA based ‘Rac GLISA 
activation assay’ which is coated with RBD domain of Rac1-family effector 
proteins, where only the active GTP-bound form of the Rac-family protein, but 
not the inactive GDP-bound form will bind to the plate. The protocol provided by 
the company was followed with minor changes. 
Day 7 BMDCs were serum starved for two days in IMDM medium containing 
0.5% FCS. On day 9 BMDC were completely serum starved for at least 4h, 
harvested and 5x106 were lysed in 100µl G-LISA Buffer prepared according to 
manufacturer’s instructions and immediately frozen in liquid nitrogen. 10µl of 
each sample was removed for measuring the protein concentration with 
Precision Red™ Advanced protein assay reagent read in an ELISA reader at 
600nm. The concentration of lysates was adjusted to 0.5mg/ml and 50µl was 
used per well set up in triplicates. After antibody incubation the plate was 
extensively washed with the provided wash Buffer 6 times and in between 
inverse centrifuged to dry the plate to lower background signal. Signal intensity 
was measured at a Luminometer at 600nm.  
 
2.2.7 Immunological methods 
2.2.7.1 Antigen uptake 
2x105 BMDC in 200µl IMDM/medium were left to adhere for one hour at 37°C in 
a 96 well flatbottom. Medium was replaced by medium supplemented with 
either 200µg/ml Dextran coupled to FITC or with 2µg/ml OVA labeled Alexa 
647, respectively. BMDCs were incubated for 30min at 37°C and as a negative 
control for the same period of time at 4°C. BMDC were harvested with 2mM 
EDTA/PBS and stained with a CD11c-PE conjugated mAB. All samples were 
set up in triplicates and 20,000 events were recorded in a live gate by FACS 
Canto and evaluated by FlowJo software.  
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2.2.7.2 Purification of CD11c positive cells out of BMDC culture 
For T cell co culture assays the BMDC culture was purified for the CD11c 
positive cells only by AutoMACS separation. On day 7 BMDC were harvested 
and 108 in 500µl MACS and 100µl CD11c microbeads for 15min at 4°C 
incubated, washed twice with MACS buffer and separated from the negative 
fraction by AutoMACS with the program ‘possels’. The positive fraction was 
counted and used for in vitro studies. Staining with anti CD11c antibody and 
FACS analysis confirmed 95 to 98% purity of cells. 
 
2.2.7.3 Purification of CD8 and CD4 cells 
OVA antigen specific CD8 and CD4 positive T cells were isolated out of the 
spleen of OT-I and OT-II mice respectively. 48hrs before organ harvest the OT-I 
mouse was injected i.p. with 300µg anti NK1.1 antibody to deplete the NK and 
NKT cells. Prior 0.6g Nylon Wool in a 10ml syringe was equilibrated with RPMI 
medium without air bubbles for at least for an hour at 37°C. Spleens were 
minced through a large pored (250µm) metal sieve with a stamp of a syringe, 
centrifuged and taken up in 5ml medium, which was then transferred to nylon 
wool to retain B cells and myeloid cells. After at least 45min at 37°C the 
enriched T cells were flushed out of the syringe with 20ml medium, centrifuged 
at 1500rpm for 10min and incubated in 1ml ACK lysis buffer for 2min at room 
temperature to destroy the red blood cells. For the purification with the 
AutoMACS, 108 cells from the enriched spleen of the OT-I or OT-II were 
incubated with 500µl MACS Buffer and 50µl CD8 MicroBeads or CD4 
MicroBeads, respectively for 15min at 4°C. The cells were washed twice with 
MACS Buffer to remove unbound microbeads, send through a cell strainer 
(40µm pore size) and selected with the AutoMACS using the program ‘possels. 
The positive fraction was further employed in the in vitro studies. Staining with 
CD8 or CD4 antibody and FACS analysis confirmed 95 to 98% purity of cells. 
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2.2.7.4 Antigen presentation 
 On day 7, 2x105 wt and FHL2-/- BMDCs purified by AutoMacs using CD11c 
microbeads as described before in 2.2.7.2 were seeded in 100µl per well in a 
96 well flatbottom. After at least 45min at 37°C to let them allow adhering, 50µl 
medium was added to the BMDC containing OVA to reach a final concentration 
of 0, 0.01, 0.1, or 1mg/ml for 2hrs. A total of 1x105 in 50µl purified naive CD4+ 
and CD8+ T cells from OT-II and OT-I mice, respectively, were co-cultured with 
BMDCs. Twenty-four hours later, supernatants were collected and stored at -
20°C.  
 
2.2.7.5 IL-2 ELISA 
Supernatants collected from antigen presentation assay were subjected to a 
commercially available quantitative IL-2 a read out for T cell activation. A 96 
well ELISA plate flatbottom plate was coated with 50µl per well purified anti-IL-2 
first antibody diluted 1:500 in Coating Buffer having a final concentration of 
1µg/ml and incubated for 1h at 37°C. It was washed for four times with PBS and 
in between inverse centrifuged (1600rpm, 2min) to dry them more. This washing 
procedure was performed between all incubation steps. Unspecific binding sites 
were blocked with 50µl 1%BSA/PBS for 30min at RT. An IL-2 standard curve 
was established with recombinant IL-2 starting from 40ng/ml in a three fold 
dilution going down to 6pg/ml in RPMI medium. 100µl of the supernatants of the 
samples from the antigen presentation assay were added in triplicates to each 
well, and incubated at 4°C over night. 500ng/ml biotinylated rat anti-mouse IL-2 
secondary antibody was diluted 1:1000 in PBS and 50µl added to the samples 
one hour at 37°C. Streptavidin conjugated with HRP diluted 1:1000 in PBS was 
added for 30min at 4°C. Peroxidase substrate ABTS was diluted in ABTS buffer 
to receive a final concentration of 1mg/ml and 2µl 30% H202 was added per ml 
ABTS and the resulting green product is photometrically read in an ELISA 
Reader at 405nm. 
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2.2.7.6 T cell proliferation assay 
On day 7, 4x105 in 200µl IMDM medium wt and FHL2-/- BMDCs purified by 
AutoMacs using CD11c microbeads described before, were plated in a 48 well 
flatbottom per well. After two hours BMDC were pulsed with 100µl OVA with a 
final concentration of 1mg/ml or medium without OVA for 2 h. Purified CD4+ 
and CD8+ T cells from OT-II and OT-I mice, respectively, were labeled with 
1µM CFSE for 10min at 37°C and the reaction was stopped by FCS. The cells 
were washed and 2x105 T cells were added to each well in 200µl medium. 
Three days later, proliferation was assessed by flow cytometry counterstaining 
with CD4 and CD8 Abs. 
 
2.2.8 Statistics 
Statistics were calculated with Excel and SPSS. Error bars indicated Standard 
error of the mean (SEM). The Students T-test was used to analyze data for 
significant differences. P-values <0.05 were regarded as significant. And 
indicated in the figures as follows: *p≤ 0.05, **p≤0.01, ***p≤0.001. 
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3. Results 
 
3.1 Nuclear localization of FHL2 is lost in mature but not immature 
BMDC following stimulation with CCL19 
FHL2 deficient mice display wound healing disturbance due to defective 
migration of fibroblasts (Wixler et al., 2007). On the other hand, loss of FHL2 
activity is associated with increased epithelial cell migration in intestinal 
epithelium, which might allow eliminating of deleterious cells from proliferating 
crypt more efficiently and reducing the risk of tumorigenesis (Labalette et al., 
2010). FHL2 is known to associate with components of the actin cytoskeleton 
(Li et al., 2001), which could have an effect on the morphology of the cell (Bai et 
al., 2005). These published observations prompted us to initially study the role 
of FHL2 as a regulator of DC migration.  
In order to study DC functions in the mouse, DCs are usually generated in vitro 
out of BM precursors. In the presence of GMCSF, the hematopoietic stem cell 
will differentiate into DC defined by the expression of CD11c, a specific integrin 
alpha x. Therefore we always stained DC for CD11c for flow cytometric 
analysis, and gated on the CD11c positive population, so that only DCs were 
analyzed further (Fig 3.1, upper panel). After seven days in culture, BMDC are a 
heterogenous population: Although no additional external stimulus was present, 
a small fraction (usually between 10-15% of DC) show high expression levels of 
maturation markers (Fig. 3.1, lower panel; Petersen et al., 2000). Staining DCs 
with maturation markers CD86 and MHCII, three populations are visible by flow 
cytometry: a negative, an intermediate and a positive population. Especially, the 
number of cells in the gate of the bright population increases, after the addition 
of maturation reagents like LPS and TNF-α (45.9% and 19.6%, respectively 
versus 10.4%), which is even higher after the incubation with LPS. This is most 
likely caused by mitogenic factors present in FCS, because authors of Lutz and 
Rossner (2007) suspected high levels of glutamic oxaloacetic transaminase and 
lactate dehydrogenase correlated with a very large proportion of mature DC 
within the cultures, whereas low levels of these enzymes correlated with an 
inhibition of DC outgrowth. Other groups could also observe morphological 
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differences in BMDC culture (Burns et al., 2004). A high proportion of DC even 
in the absence of LPS provided sufficient stimulus for DC adhesion, 
polarization, and podosome formation, suggesting partial maturation. 
 
 
Figure 3.1: DCs generated out of BM show partial maturation. A day seven BMDC culture 
was incubated with 100ng/ml LPS and 30ng/ml TNF-α for 24hrs. BMDCs were harvested as 
described in Material and Methods 2.2.1.4, stained for CD11c, CD86 and MHCII, and analyzed 
by flow cytometry. In the upper panel, the gating strategy is depicted that we applied in all 
experiments: By plotting FSC versus SSC, a live gate was drawn, which contained the 
presumably living cells. Only these were analyzed for CD11c expression, where we gated on 
the CD11c positive fraction of cells. 
 
 
The localization of FHL2 within a cell could give us information of what kind of 
function FHL2 is playing. FHL2 can act as a co-activator or –repressor of 
several transcription factors, or it binds to integrins which link the ECM and the 
actin cytoskeleton. To determine FHL2 expression and the conformation of the 
actin cytoskeleton we stained immature or LPS-matured wt BMDC for FHL2 and 
phalloidin. Phalloidin is a toxin derived from a mushroom called death cap that 
binds to actin filaments much more tightly than to actin monomers, and can give 
us information about the structure of the actin cytoskeleton within a cell 
(Cooper, 1987; Sampath and Pollard, 1991). LPS treatment induces via TLR 4 
(Akira et al., 2001) a signal cascade that leads to DC maturation. As maturation 
Results 
 
55 
progressed an increasing proportion of DC assumed rounded cell morphology 
with multiple membrane-ruffles covering the surface of the cell (Burns et al., 
2004).  
We could observe the same observe in the LPS-matured culture where a higher 
number of DCs have a smaller and rounded appearance compared to the 
immature culture made visible by phalloidin staining (Fig. 3.2 A). Both immature 
and mature BMDC express FHL2, which localizes to the nucleus (Fig. 1A, upper 
and lower left corner). Before we further analyze whether FHL2 has a functional 
role in DC migration, we wanted to determine localization of FHL2. Therefore, 
we stained mature and immature BMDC for FHL2 that were stimulated with the 
CCR7 chemokine receptor ligand CCL19. In immature BMDC, CCL19 treatment 
did not alter FHL2 localization, which remained mainly in the nucleus (Fig. 3.2. 
A, upper right corner) Interestingly, CCR7 ligation in mature DC led to loss of 
nuclear localization of FHL2 redistributing towards the cell membrane, which we 
could mainly found in small rounded cells of the culture. Together, this indicates 
that the migratory chemokine CCL19 influences FHL2 localization and strongly 
suggests a functional role of FHL2 in DC migration. 
 
Before we further functionally addressed the role of FHL2 in CCL19 induced 
processes in DC migration, we wanted to confirm loss of FHL2 in FHL2-
deficient mice (Chu et al., 2000a). Here, we performed RT-PCR on various 
tissues and in vitro generated BMDC of wt C57BL/6 and FHL2-/- mice (Fig. 3.2 
B). FHL2 mRNA was highly expressed in the heart, skeletal muscle, 
gastrointestinal tract, lung and at lower levels in BMDC of wt mice, while 
expression was lost in FHL2-deficient mice. Moreover, FHL2 protein was not 
detectable by western blot in heart tissue that has the highest levels of FHL2 
expression in wt mice (Chu et al., 2000b), Fig. 3.2 C). Since expression of FHL2 
was relatively low in BMDC (Fig. 3.2 B), we performed IP of FHL2 protein with a 
monoclonal anti-FHL2 ab out of wt and FHL2-/- BMDC protein lysates, and 
loaded the concentrated lysate on a SDS-PAGE and performed western blot 
against FHL2. As expected we could confirm that FHL2 expression is not 
detectable at the protein level in FHL2-/- BMDC (Fig. 3.2 D). 
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Figure 3.2: Nuclear expression of FHL2 in mature BMDC is reduced following stimulation 
with CCL19. (A) Day 7 BMDC were either matured with LPS (100ng/ml) for one day or left 
untreated (immature). Subsequently they were left to adhere on glass cover slips in the 
presence or absence of CCL19 (10ng/ml) for 1h, fixed and stained with a polyclonal FHL2 
specific antibody (red), phalloidin (green) and DAPI (blue). (B) Detection of FHL2 mRNA by RT-
PCR in day 7 wt and FHL2-/- immature BMDC, heart, colon, skeletal muscle and lung using 
primers for exon 1. As positive control and loading reference ß-actin mRNA was detected. (C) 
Western blot analysis of FHL2 protein in cardiac muscle of wt and FHL2-/- mice. Detection of 
actin served as loading control. (D) IP of FHL2 and following analysis by western blot of wt and 
FHL2-/- BMDC. The data shown here is representative of three or more independent 
experiments. 
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3.2 FHL2-/- BMDC display enhanced migratory directionality, speed and 
persistence in vitro 
We showed that in mature DCs the actin conformation is changed to a rather 
small and rounded appearance compared to an immature DC. In the presence 
of CCL19, FHL2 localizes differently in this cell type rather in the cytoplasm than 
in the nucleus without CCL19 ligation. So, it seems FHL2 is involved in the 
conformation of the actin cytoskeleton of DC. The actin cytoskeleton needs to 
be rearranged in the cell depending on the need for slower or faster migration.  
To measure the influence of FHL2 expression on chemotactic directionality, 
migratory speed and directional persistence of BMDC more closely, we used 
timelapse video microscopy (Fig. 3.3). Timelapse microscopy can image the 
same object e.g. a cell at regular time intervals over several hours and compile 
the images into a movie. So, live-cell imaging enables us to monitor cell 
movements over time. Images are taken in real time and allows the speed of 
single cells and the distance they have covered to be measured directly in vitro. 
Briefly, immature BMDC were transferred into collagen-coated IBIDI µ-slide 
chambers and images were taken every 15s for a period of one hour after 
establishing a CCL19 gradient. Quantitative analysis of single BMDC tracks 
showed that both wt and FHL2-/- BMDC stayed nearly in the same position 
meaning they show hardly directionality when no chemokine gradient was 
applied (Fig. 3.3 A, upper left and right corner). Once the chemokine gradient 
was applied, both wt and FHL2-/- BMDC showed directed migration towards 
CCL19 from the right (Fig. 3.3 A, lower left and right panel). FHL2-/- BMDC 
covered a significantly longer distance (mean distance 100µm; n=90), 
measured as a direct line from their point of origin, than wt BMDC (mean 
distance 53µm; n=75) (Fig 3.3 B, left panel). This was partly due to a less 
torturous migratory path (Fig 3.2 A), but also to a significantly increased 
migratory speed: wt BMDC showed a mean migratory speed of 40µm/h and 
FHL2-/- BMDC 140µm/h (Fig 3.3 B, right panel). Furthermore, FHL2-/- BMDC 
showed a higher degree of directional persistence (Fig 3.3 A). 
Thus, timelapse video-microscopy conclusively showed that FHL2 has an 
impact on DC migration, namely that FHL2 loss leads to increased migratory 
speed, and also increased persistence and directionality. 
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Figure 3.3: Higher migratory speed and directionality towards a CCL19 gradient in FHL2-
/- BMDC compared to wt BMDC. Wt and FHL2-/- BMDC were generated as described. At day 
7 immature BMDC were harvested and 105 BMDC were left to adhere in collagen-coated IBIDI 
µ-slides for 45min at 37°C and filmed simultaneously. After 45min a CCL19 gradient was 
established and BMDC were filmed for an additional 60min. Time-lapse images were taken 
every 15s. (A) Single tracks of migrating BMDC analyzed using the Track-it software. (B) Mean 
distance and speed of migrating BMDC calculated by the Track-it software from Olympus. In 
each group the tracks of at least 70 BMDC were analyzed. Values are depicted as mean and 
error bars +/-SEM. Statistical significance was calculated using a Student’s t-test: NS not 
significant, *p≤ 0.05, **p≤0.01, ***p≤0.001. The data shown here is representative of three or 
more independent experiments. 
 
 
3.3 Enhanced in vitro and in vivo migration of FHL2-deficient BMDC 
We wanted to confirm our results and to substantiate our conclusion gained 
from Time lapse microscopy by an additional methodology i.e. transwell. DCs 
were plated on an insert with a pore size of 5µm in transwells, which was placed 
in a well of a 24 well plate, making contact with the media filled in the bottom 
chamber. Here, the number of cells arrived in the bottom of the 24 well plate 
well which is quantified by flow cytometry correlates to their migratory capacity. 
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To examine the effect of FHL2 deficiency on CCL19-induced DC migration, 
immature wt or FHL2-/- BMDC were placed in the upper chamber of a transwell 
and left to migrate towards CCL19 or medium alone. When no CCL19 was 
present in the lower chamber, only a very low number of cells could be detected 
(Fig. 3.4 A). Both wt and FHL2-/- BMDC migrated in a CCL19 dependent 
manner as significantly more BMDC were counted when CCL19 was present in 
the lower well. Control experiments demonstrated when chemokine was added 
only to the upper or the upper and lower chamber no increased migration above 
basal levels was observed (Fig. 3.4 C). This was done to exclude that CCL19 
by itself might influence of the morphology of BMDC so that they could pass 
through the membrane more easily. This would not have been a matter of active 
migration but rather dropping through the pores of the membrane. So, we can 
assume that this effect was specific to CCL19 attracting BMDC to the lower 
chamber, where they actively migrated to. Furthermore, significantly more 
FHL2-/- BMDC migrated into the lower chamber in the given time period than wt 
BMDC indicating that FHL2 deficiency significantly increases the CCL19-
induced migration rate of BMDC (p value = 0.004). This difference was still 
significant when BMDC were matured either with LPS or TNF-α (Fig. 3.4 B). 
This difference between wt and FHL2-/- BMDC was even higher when matured 
with TNF-α when FHL2-/- BMDC showed approximately three fold increase in 
migration (Fig. 3.4 B, lower panel). Both demonstrated increased migratory 
speed after stimulation with TNF-α or LPS stimulated BMDC, but stimulated wt 
BMDC could never speed up to levels of immature FHL2-/- BMDC. Hence, we 
were able to confirm our results obtained from timelapse microscopy by 
transwell assays, i.e. FHL2-/- BMDC show increased migration towards CCL19. 
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Figure 3.4: FHL-/- BMDC show enhanced migration in a transwell assay towards CCL19, 
even after stimulation with LPS and TNF-α. Wt and FHL2-/- BMDC were generated. (A) At 
day 7, immature BMDC (A), LPS and TNF-α-matured (B) were harvested; and 2.5x105 BMDC 
were cultured in 100µl medium containing 0.5% BSA in the upper chamber of a 5µm pore 
transwell insert. The bottom chamber was filled with 600µl medium containing 0.5% BSA alone 
or supplemented with 10ng/ml CCL19. After 3h, migrated BMDC were harvested from the lower 
chamber and stained for CD11c. The amount of migrated CD11c+ BMDC was quantified by flow 
cytometry by addition of a set amount of calibration beads and calculated as follows: total 
migrated BMDC = (beads total * BMDC sample)/beads sample. Values are depicted as mean 
and error bars +/-SEM. Statistical significance was calculated using a Student’s t-test: NS not 
significant, *p≤ 0.05, **p≤0.01, ***p≤0.001. The data shown here is representative of three or 
more independent experiments. 
 
 
Directional migratory speed in DC is known to be regulated amongst others by 
CCR7 (Ohl et al., 2004). Since FHL2 can act as a transcriptional co-activator or 
–repressor (Johannessen et al., 2006; Lai et al., 2006; Muller et al., 2000; 
Muller et al., 2002) and thus might affect CCR7 expression, we investigated 
whether CCR7 expression was increased in FHL2-/- BMDC. However, staining 
of immature BMDC with CCL19-IgG fusion protein (Fig. 3.5 A) did not reveal 
differences in CCR7 expression levels between wt and FHL2-/- BMDC. This 
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indicates that the enhanced CCL19-induced migration of FHL2-/- BMDC was 
not due to altered CCR7 surface expression. Additionally, the expression levels 
of CCR7 remained the same between wt and FHL2-/- BMDC after incubation 
with LPS and TNF-α (Fig. 3.5 B).  CCR7 was upregulated in both cell types, and 
with respect to TNF-α the expression of CCR7 in both cell types was slightly 
more in contrast to LPS matured. 
 
 
Figure 3.5: CCR7 expression is the same between FHL2-/- and wt BMDC.  Day 7 immature 
(A), matured with LPS and TNF-α (B) wt and FHL2-/- BMDC were stained with CCL19-Fc and 
anti-HuFc-PE or with anti-HuFc alone as a negative control and analyzed by flow cytometry. (A) 
CCR7 expression shown as a histogram. CCL19-Fc and anti-HuFc-PE (black lines) or anti-
HuFc alone (grey filled). (B) Expression levels are shown as mean fluorescence intensity (MFI). 
The data shown here is representative of three or more independent experiments. 
 
 
In vitro DC migration assays only partially resemble DC migration in vivo (Sixt et 
al., 2006). Therefore, we determined whether FHL2-/- BMDC also had altered 
migratory properties in vivo. To this end we injected equal amounts of immature 
or TNF-α matured (Cumberbatch et al., 1999; Cumberbatch and Kimber, 1992) 
wt and FHL2-/- BMDC that were fluorescently labeled with SNARF (FHL2-/-) 
and CFSE (wt) into the footpad of C57BL/6 recipient mice and quantified the 
number of CD11c positive BMDC that migrated into the draining popliteal LNs 
within 26h. In vivo studies suggest that the journey to the lymph node takes 
between 3–24 h (Kupiec-Weglinski et al., 1988; Roake et al., 1995) by which 
time DC express high levels of MHC complexes, and are functionally primed for 
Results 
 
62 
optimal interaction with T cells (Sallusto and Lanzavecchia, 1994). Both 
immature (Fig. 3.6 A, right panel) and TNF-α matured (Fig. 3.6 A, left panel) 
FHL2-/- and wt BMDC arrived in the draining LN in the given period of time, but 
the number of FHL2-/- BMDC was significantly higher. More interestingly, this 
effect was independent of the maturation status of the BMDC (Fig. 3.8) 
indicating that FHL2 deficiency also regulates migration of immature DC. We 
can also assume that this is not because of a better response to CCL19 or 
CCL21 because CCR7 is equally expressed on wt and FHL2-/- BMDC (Fig. 3.4, 
see Discussion). Dye swap experiments excluded possible dye specific effects, 
which can be seen in Figure 3.6 B: Representative dot plot depicting SNARF+ 
FHL2-/- and CFSE+ wt BMDC and the other way around within the recovered 
CD11c+ DC population. Regardless of which stain we used, SNARF or CFSE, 
FHL2-/- showed a higher migratory rate into the LN. To rule out that the loss of 
FHL2 had an effect on DC viability and therefore we could recover more FHL2-
/- BMDC out of the draining LN, we examined cell survival with the help of an 
MTT assay in vitro over the same period of time, i.e. 26h (Fig. 3.6 C). Here, we 
could not see an advantage of FHL2-/- BMDC over wt BMDC with respect to 
survival. Thus, the increased number of FHL2-/- BMDC recovered from the 
popliteal LN was not due to a survival advantage over wt BMDC. Collectively, 
this indicates that FHL2-deficiency in BMDC leads to enhanced migratory 
activity both in vitro and in vivo. 
 
Results 
 
63 
 
Figure 3.6: Enhanced in vivo migration of FHL2-/- BMDC. (A) Immature (left panel) or TNF-α 
matured (right panel) BMDC were harvested and wt and FHL2-/- BMDC were labeled with 
CFSE and SNARF, respectively. Wt and FHL2-/- BMDC were mixed at a ratio of 1:1 and 
injected into the footpad of wt recipient mice. After 26h single cell suspensions of the draining 
popliteal LNs were prepared, stained for CD11c and analyzed by flow cytometry. The total 
number of CD11c+ wt BMDC recovered from an individual popliteal LN was set to 1 and the 
number of FHL2-/- BMDC per wt BMDC is shown as fold increase. (B) Representative dot plot, 
gated on CD11c positive DC is shown. Numbers indicate the percentage of CFSE positive wt 
and SNARF positive FHL2-/- BMDC or the other way around within the DC population in the 
popliteal lymph node. (C) 2x105 wt and FHL2-/- BMDC in six replicates were plated in a volume 
of 100µl in a 96 well plate. 24hrs later 10µl of MTT solution was added to each well. After 4hrs 
100µl Solubilization Buffer was added and incubated overnight at 37°C. Survival was 
determined in a photometer at 570nm. Values are depicted as mean and error bars +/-SEM. 
Statistical significance was calculated using a Student’s t-test: NS not significant, *p≤ 0.05, 
**p≤0.01, ***p≤0.001. The data shown here is representative of three or more independent 
experiments. 
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3.4 FHL2-/- BMDC express more lamellipodia than wt BMDC due to 
increased Rac1 activation 
Cell locomotion depends on the protrusion of the leading edge, the traction of 
the cell body, and the retraction of the tail. For all these individual processes 
reorganization of the actin cytoskeleton is necessary (Keren et al., 2008; Le 
Clainche and Carlier, 2008). In detail, cells that are stationary and hardly 
moving express mostly stress fibers. In order to initiate cell migration slender 
cytoplasmic projections are formed that allow moderate migration. In very 
mobile cells like keratinocytes of fish and frog, also actin projections are called 
lamellipodia are formed with an underlying two-dimensional actin mesh. With 
respect to DC these projections are mostly seen in a mature DC after trigger of 
PRRs, when the DC needs to carry the antigen to the LN as fast as possible. 
We could also see a different conformation of the actin cytoskeleton after 
stimulation with LPS (Fig. 3.2 A, lower panel) and this lead most likely to 
enhanced cell migration (Fig 3.4, upper panel).  
To answer the question, if there is a different reorganization of the actin 
cytoskeleton in FHL2-/- BMDC, the actin cytoskeletal conformation of immature 
FHL2-/- and wt BMDC was examined by immunofluorescent staining with 
phalloidin (Fig. 3.7 A). The morphology of FHL2-/- and wt BMDC differed 
significantly: While 90% of immature wt BMDC on collagen showed long 
protruding filopodia and only less than 10% of cells were small and veiled (Fig. 
3.7 A, upper panels), up to 50% of the cells in an FHL2-/- BMDC culture 
showed this phenotype (Fig. 3.7 A, lower panels). The quantification is found in 
Fig 3.7 A, right panel. As mentioned before, the BMDC culture system yields a 
heterogeneous population of BMDC where a small proportion of DC matured 
spontaneously. This we could see in our own culture system, which is a very 
mixed population of different cell types and not a pure population, which is 
reflected by the numbers after counting the different morphologies. In this 
context it is interesting to note that authors from Bai et al. (2005) could also 
observe a difference in organization of the cytoskeleton of osteoclasts isolated 
out of wt and FHL2-/- mouse. 
 
Fluorescent labeled phalloidin can be used to quantitative the amount of 
filamentous actin there is in a cell (Cooper, 1987; Koestler et al., 2009). 
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Phalloidin preferentially binds to polymerized F-actin, while lammellipodia are 
arranged of a more branched F-actin structure whereas in filopodia the structure 
of the actin cytoskeleton is more organized  (Le Clainche and Carlier, 2008), 
therefore lamellipodia stain more strongly with phalloidin. The amount of F-actin 
was compared quantitatively by flow cytometry in serum starved immature and 
TNF-α matured wt and FHL2-/- BMDC (Fig 3.7 B). FHL2-/- BMDC showed 
significantly higher amounts of polymerized F-actin than wt BMDC. The 
difference between wt and FHL2-/- in polymerized F-actin was even more 
pronounced in TNF-α matured BMDC. So, by a different approach we could 
confirm our previous observation that the cytoskeleton in FHL2-/- exhibits 
differences to wt BMDC. This might explain why we could see elevated 
migration of FHL2-/- BMDC in timelapse Microscopy, transwell assay and in 
vivo. 
 
The loss of filopodia and formation of veils or lamellipodia is associated with DC 
maturation and is thought to allow their rapid migration into secondary lymphoid 
organs (Burridge and Wennerberg, 2004; Calle et al., 2004b; Pollard and 
Borisy, 2003). The formation of protrusions at the leading edge of DC during 
migration is controlled by the small GTPases Rac and Cdc42 (Swetman et al., 
2002). In detail, Cdc42 activity induces filopodia in immature DC, while Rac 
activity induces the loss of filopodia and formation of lamellipodia upon 
maturation (Burns et al., 2004). Generally small GTPases cycle between a 
GTP-bound active form and a GDP-bound inactive form. When bound to GTP 
they interact with their downstream targets, which include protein kinases, 
activators of actin polymerization as well as adaptor proteins. To analyze 
whether the observed increased migration of FHL2-/- BMDC was due to 
increased Rac1 activation, we determined the amount of Rac-GTP in immature 
wt and FHL2-/- BMDC by an ELISA based Rac1 activation assay. We found a 
significantly higher amount of active Rac1 in FHL2-/- BMDC compared to wt 
BMDC (Fig. 3.7 C), indicating that in FHL2-/- BMDC deregulated control of the 
Rac GTPase is responsible for the lamellipodia formation observed leading to 
migratory changes. 
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Rho-kinase, an effector of the small GTP-binding protein Rho, plays an 
important role in various cellular functions including vascular smooth muscle 
contraction, proliferation, and migration as well as inflammatory cell mobility 
(Oka et al., 2007). In addition, FHL2 is known to translocate into the nucleus in 
RhoA-dependent manner (Muller et al., 2002). Therefore we wanted to know 
whether Rho is involved in the accelerated migration of FHL2-/- BMDC. To 
address this question, we blocked Rho with several inhibitors. Y27632 is a 
potent, ATP-competitive inhibitor of Rho-associated protein kinases including 
p160ROCK and ROCK-II (Darenfed et al., 2007; Ishizaki et al., 2000). Fasudil is 
a potent inhibitor of Rho-associated kinase II and additionally inhibits protein 
kinase C-related kinase 2, mitogen- and stress-activated protein kinase, and 
mitogen activated protein kinase-activated protein kinase 1b (Huentelman et al., 
2009). CCG-1423 is a specific inhibitor of Rho pathway-mediated signaling and 
activation of serum response factor (SRF) transcription (Evelyn et al., 2007).  
Wt and FHL2-/- BMDC were incubated together with these inhibitors during the 
migration towards CCL19 in a Transwell. Y27632 did not change migratory 
behavior of wt and FHL2-/- BMDC (Fig. 3.8 A). Fasudil and CCG-1423 seem to 
have a slight effect on the migration speed of wt and FHL2-/- (Fig. 3.8 B), but 
diminished migration level to the same extent. Also another group concluded 
that the Rho family GTPases Rac1 and Rac2 but not Rho itself control the 
formation of dendrites in mature DCs, their polarized short-range migration 
toward T cells, and T cell priming (Benvenuti et al., 2004). 
So, we can assume FHL2 exhibits its function in BMDC independent of Rho 
signaling, but show higher amounts of activated Rac1, which is known to induce 
lammellipodia which is formed to a higher number in FHL-/- BMDC culture.  
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Figure 3.7: FHL2-/- BMDC form more lamellipodia and have higher levels of Rac 
activation. (A) At day 7 immature BMDC were left to adhere on a collagen-coated cover glass 
for 2h. Then cells were fixed, permeabilized and stained with phalloidin. Left panel: Pictures of 
wt and FHL2-/- BMDC (40x). Right panel: Percentage of small, veiled BMDC, lacking filopodia 
within the immature wt BMDC population compared to immature FHL2-/- BMDC. n = the amount 
of BMDC analyzed in each group. (B)  On day 7, BMDC were cultured for further two days in 
medium containing 0.5% FCS. At the same time maturation was induced by 30ng/ml TNF-α. 
BMDC were stained intracellularly with PhalloidinAlexa647 for 30min on ice. Here, the mean 
fluorescence intensity of Phalloidin gated on CD11c+ cells is depicted. (C) Day 7 immature 
BMDC were cultured in medium containing 0.5% FCS. On day 9 BMDC were completely serum 
starved for at least 4h and then lysed. The protein lysate was investigated for Rac activity in an 
ELISA coated with Rac-GTP-binding protein. Signal intensity was measured with a luminometer 
at 600nm, and Rac activity is shown as relative luminometric units (RLU). Values are depicted 
as mean and error bars +/-SEM. Statistical significance was calculated using a Student’s t-test: 
NS not significant, *p≤ 0.05, **p≤0.01, ***p≤0.001. The data shown here is representative of 
three or more independent experiments. 
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Figure 3.8: FHL-/- DC migration is independent of Rho signaling. (A,B) Wt and FHL2-/- BMDC 
were pre incubated with 2µM and 10µM Y27632 (A), 2.5µM Fasudil and 2mM CCG-1432 (B) for 
one hour in the insert and then transferred on a transwell. In the lower well 200ng/ml CCL19 
was present as well as the previously mentioned inhibitors with the corresponding 
concentration. 
 
3.5 FHL2 deficiency does not lead to spontaneous BMDC maturation 
Both increased migration and the formation of lamellipodia are associated with 
DC maturation (Burns et al., 2004). FHL2 known to be a co-activator or –
repressor of several transcription factors e.g. NF-kB it could govern maturation 
of BMDC. To determine whether in the absence of FHL2, leads to 
spontaneously maturation, the expression of costimulatory molecules and MHC 
class molecules as well as the production of pro-inflammatory cytokines by 
immature wt and FHL2-/- BMDC was examined. However, the expression levels 
of CD40, CD80, CD86, MHC class I and II (Fig. 3.9 A, upper two rows) did not 
differ between immature wt and FHL2-/- BMDC. Furthermore, these markers 
were upregulated to the same extent on both wt and FHL2-/- BMDC by 
incubation with LPS or TNF-α (Fig. 3.9 A, four lower two rows). BMDC treated 
with TNF-α showed overall higher expression levels compared to LPS 
stimulation, which have been observed by other groups  (Landi et al., 2010).  
Also the ability to produce IL-12 and TNF-α at basal levels did not differ 
between wt and FHL2-/- BMDC (Fig. 3.9 B), indicating that FHL2-/-BMDC did 
not exist in a more mature state. As a positive control, we incubated BMDC with 
LPS, because it is known that LPS is a potent stimulator of IL-12 and TNF-α 
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production via TLR (Brightbill et al., 1999; Dumitru et al., 2000). Here, 
incubation with LPS induced the production of IL-12 and TNF-α to about 35% in 
wt and FHL2-/- BMDC. But also there we could not see a difference in cytokine 
production after LPS stimulation between wt and FHL2-/- BMDC. Incubation of 
BMDC with TNF-α did not have an effect on cytokine secretion. Together, these 
data show that the enhanced migratory capacity towards CCL19 of FHL2-/-
BMDC is associated with the formation of lamellipodia, but does not correlate to 
their maturation status. 
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Figure 3.9: FHL2-/- BMDC are not constitutively mature. (A) Immature and mature wt and 
FHL2-/- day 7 BMDC were stained for the maturation markers CD40, CD80, CD86, MHC class I 
and II. Black open histograms: specific Ab staining, grey filled histograms: isotype control. (B) 
Untreated and LPS matured wt and FHL2-/- day 7 BMDC were incubated for 5h with Monensin 
and Brefeldin A, and stained intracellularly with Abs against IL-12 and TNF-α, gated on CD11c+ 
cells. The percentage of BMDC producing IL-12 and TNF-α is shown. Values are depicted as 
mean and error bars +/-SEM. Statistical significance was calculated using a Student’s t-test: NS 
not significant, *p≤ 0.05, **p≤0.01, ***p≤0.001. The data shown here is representative of three or 
more independent experiments. 
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3.6 Antigen uptake and presentation in BMDC are not influenced by 
FHL2 
Antigen uptake by DCs is essential for the presentation of antigens by MHC 
molecules to T cells in the LN in order to evoke an efficient immune response. 
Immature DCs endocytose avidly through a variety of mechanisms, including 
‘nonspecific’ uptake by constitutive macropinocytosis and ‘specific’ uptake via 
receptor-mediated endocytosis and phagocytosis (Trombetta and Mellman, 
2005). The exact mechanism of antigen uptake is not completely understood, 
but it is known that actin and its regulation by Rho family GTPases play 
important roles in mediating phagocytosis and macropinocytosis. For example, 
macropinocytosis involves the extension of membrane ruffles, which requires 
polymerization and reorganization of actin (Caron and Hall, 1998). Rac has an 
important role in the constitutive formation of macropinosomes in DCs but may 
be required downstream of membrane ruffling (Nobes and Marsh, 2000; West 
et al., 2000). DCs developmentally regulate endocytosis at least in part by 
controlling levels of activated Cdc42 (Garrett et al., 2000). We know from our 
own observations that loss of FHL2 in BMDC leads to increased migration 
probably due to higher amounts of activated Rac which causes differential 
organization of actin cytoskeleton. Thus, we thought that also loss of FHL2 
might affect antigen uptake in BMDC. 
We, therefore, compared antigen uptake by immature wt and FHL2-/- BMDC, 
and as model antigens we used OVA and Dextran. Both are endocytosed by 
two different ways: OVA is endocytosed receptor mediated (Kindberg et al., 
1990), and Dextran is internalized by macropinocytosis (West et al., 1999). To 
this end, BMDC were incubated with fluorescently labeled Dextran or OVA for 
30min at 37°C or as a negative control 4°C, and fluorescence intensity was 
analyzed in flow cytometry (Fig. 3.10 A). When BMDC were incubated with 
OVAAlexa647 at 4°C (dashed lines) the histogram overlapped with unstained 
control (grey filled) which means they were not able to take up antigen. This 
changed dramatically when the BMDC were incubated with OVAAlexa647 at 37°C, 
where a big shift to the right could be seen. When incubated with DextranFITC at 
4°C, there was a small shift compared to unstained control, meaning that they 
still endocytose antigen unspecifically. This shift was amplified when BMDC 
were incubated at 37°C. However, we did not observe any significant 
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differences in case of incubation with OVA and Dextran between wt and FHL2-/- 
BMDC, indicating that FHL2 does not influence antigen uptake in BMDC.  
 
After engulfment of antigen by DC, it undergoes through a lot of changes to 
efficiently equip them as an APC. When the DC arrived in the LN and comes 
into contact with a lymphocyte, a so called immunological synapse is formed. It 
consists of a central cluster of T cell receptors (TCRs) interacting with MHC 
molecules on DC surrounded by a ring of adhesion molecules. There are active 
changes taking place in the T cell cytoskeleton i.e. accumulation of F-actin and 
other cytoskeletal proteins in the T cell at the contact point, which result in the 
dynamic clustering of T cell surface receptors and signaling molecules at the 
interface with the APC (Grakoui et al., 1999; Pardi et al., 1992). But also DC 
actin cytoskeletal rearrangement is critical for the clustering and activation of 
resting T cells, indicating an important role for the DC cytoskeleton in the 
establishment of the immunological synapse (Al-Alwan et al., 2003; Al-Alwan et 
al., 2001). Actin reorganization is usually conducted by members of the small 
Rho GTPases. Constitutive activation of Rho GTPases in DC differentially 
modifies a lot of DC functions like adherence, chemotaxis, endocytosis, and 
also antigen presentation (Ladwein and Rottner, 2008; Shurin et al., 2005). 
Although we know that loss of FHL2 has an impact on the composition of the 
cytoskeleton and migration, but not on other processes like maturation and 
antigen uptake as discussed in the previous sections. Still we were very 
interesting to find out if this holds true for antigen presentation. We already 
know that wt and FHL2-/- BMDC provide the same amount and kind of signals 
with respect to cytokine production, co-stimulatory molecules and antigen dose, 
so a difference could only because of a differential organized cytoskeleton.  
To test whether the loss of FHL2 affects antigen presentation by DC, we 
performed co-culture assays with BMDCs and T cells. We isolated T cells out of 
the spleen of OT-I and OT-II transgenic mice, which can specifically recognize 
the OVA peptide in the context of an MHC I and MHC II molecule, respectively. 
If a T cell has recognized its specific antigen on an APC, it undergoes a huge 
transition and amongst enters the mitotic cycle to augment its number for 
effective fight against the invading organism. This behavior by T cells serves as 
a helpful measure to check for efficient antigen presentation by BMDC. 
Results 
 
73 
Therefore, they were stained with CFSE and added to FHL2-/- and wt BMDC, 
which have been pulsed before with whole OVA protein for 2hrs (Fig. 3.10 B). 
CFSE can be used to monitor lymphocyte proliferation due to the progressive 
halving of CFSE fluorescence within daughter cells following each cell division 
as seen in flow cytometer (Lyons and Parish, 1994). When there was no OVA 
present, both OT-I and OT-II T cells did not respond to the DC as seen by a 
single and very bright population (grey filled). There was no difference in the 
proliferation profile of both OT-I and OT-II T cells stimulated by FHL2-/- or wt 
BMDC, but in both cases a higher proliferation index of OT-II could be 
observed.  
 
Antigen binding to the TCR stimulates the secretion of IL-2, and the expression 
of IL-2 receptors (IL-2R). The IL-2/IL-2R interaction then stimulates the growth, 
differentiation and survival of antigen selected T cells via the activation of the 
expression of specific genes. They produce high amounts of IL-2, which works 
in an autocrine loop to drive them into mitosis (Malek and Castro, 2010). Wt and 
FHL2-/- BMDC were incubated with various concentrations of OVA, OT-I and 
OT-II T cells were then added and as a read out for efficient antigen recognition 
by T cells IL-2 release in the supernatant was assessed after 24h by ELISA 
(Fig. 3.10 C and D). BMDCs do not tend to produce IL-2 by themselves as seen 
when no OVA was present, therefore the IL-2 originated exclusively from T 
cells. At lower OVA concentrations FHL2-/- BMDC induced slightly higher IL-2 
production by OT-I and OT-II T-cells, however these differences were not 
statistically significant. Also, at higher OVA concentration, there was no 
difference in the production of IL-2 induced by wt and FHL2-/- BMDC. Together, 
based on these data we concluded that although FHL2 influences the 
conformation of the cytoskeleton and subsequently the migratory behavior of 
DC it does not influence antigen uptake or presentation or T cell activation. 
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Figure 3.10: Antigen uptake and presentation via MHCI and MHCII is not altered in FHL2-/- 
BMDC. (A) Day 7 Wt and FHL2-/- BMDC were harvested and 2x105 BMDC were left to adhere 
for 1h. BMDC were incubated with 200µg/ml DextranFITC, 2µg/ml OVA or medium only at 37°C 
or as a negative control at 4°C. After 30min cells were harvested and analyzed by flow 
cytometry. Histograms depict cells gated on CD11c. Black lines: incubation with DextranFITC or 
OVAAlexa647 at 37°C, dashed lines: 4°C control, grey filled: medium only. (B-D) Day 7 wt and 
FHL2-/- CD11c+ BMDC were either loaded with OVA or left untreated and were then co-
cultured with CFSE-labeled (B) or unlabeled (C,D) CD8+ OT-I T cells or CD4+ OT-II T cells. (B) 
4x105 BMDC were incubated for two hours with 1mg/ml OVA or medium alone. Proliferation of 
CFSE labeled CD8+ as well as CD4+ OVA-specific T cells were checked 72h later by flow 
cytometry by gating on CD8+ or CD4+ cells. Black open histograms: T cells co-cultured on 
BMDC incubated with OVA. Grey filled histograms: T cells co-cultured on BMDC without OVA. 
(C,D) After 24h of co-culture the supernatant was assayed by ELISA for IL-2. Grey bars: IL-2 
production after incubation with wt BMDC, black bars: FHL2-/- BMDC. Values are depicted as 
mean and error bars +/-SEM. Statistical significance was calculated using a Student’s T-test: 
NS not significant, *p≤ 0.05, **p≤0.01, ***p≤0.001. The data shown here is representative of 
three or more independent experiments. 
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3.7 Sphingosine-1-phosphate receptor 1 is upregulated in FHL2-/- 
BMDC 
Besides the CCR7 ligands CCL19 and CCL21, the lysophospholipid S1P also 
plays an important role in DC migration and positioning in the LN (Czeloth et al., 
2007). The S1P receptors S1PR1-4 are differentially expressed depending on 
the maturation status of DC (Czeloth et al., 2005) and this influences their 
migratory behavior. We therefore analyzed the expression pattern of the 
S1PR1-4 in immature and mature wt BMDC and FHL2-/- BMDC by qRT-PCR. 
Consistent with previous reports (Czeloth et al., 2005), we found that after 
maturation with TNF-α S1PR1 and S1PR3 mRNA levels were upregulated in wt 
BMDC, whereas S1PR4 mRNA levels were diminished and S1PR2 mRNA 
levels were unchanged (Fig. 3.11). Interestingly, in both immature and mature 
FHL2-/- BMDC we found significantly higher levels of S1PR1 mRNA (Fig. 3.11, 
upper left panel), whereas S1PR2-4 mRNA levels did not differ significantly 
from the levels in the wild type BMDC. As ligation of the S1PR1 by S1P in DC is 
associated with migration initiation or enhancement (Czeloth et al., 2005), these 
data suggest that FHL2 regulates DC migration via inhibiting the expression of 
S1PR1. 
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Figure 3.11: FHL2-/- BMDC show high expression levels of S1PR1. mRNA was isolated 
from day 7 immature or day 9 TNF-α-matured wt and FHL2-/- BMDC. The expression of 
S1PR1-4 was determined by quantitative RT-PCR. For calculation the ∆∆CT method was 
applied by normalizing to the constitutively expressed housekeeper 18s RNA. Grey bars: wt 
BMDC, black bars: FHL2-/- BMDC. Values are depicted as mean and error bars +/-SEM. 
Statistical significance was calculated using a Student’s t-test: NS not significant, *p≤ 0.05, 
**p≤0.01, ***p≤0.001. The data shown here is representative of three or more independent 
experiments. 
 
 
3.8 Downregulation of S1PR1 using siRNA and antagonist abrogates 
the increased migratory speed of FHL2-/- BMDC 
To investigate whether upregulation of S1PR1 in FHL2-/- BMDC functions as an 
accelerating receptor (Sugimoto et al., 2003), leading to the observed increased 
migration of FHL2-/- BMDC, we suppressed expression of S1PR1 by 
transfecting both immature wt and FHL2-/- BMDC with S1PR1-specific or 
unspecific control siRNA (scrambled). As expected, in FHL2-/- BMDC 
transfected with control siRNA, S1PR1 mRNA levels were significantly higher 
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compared to wt BMDC transfected with control siRNA (Fig. 3.12 A). 
Furthermore, in both wt and FHL2-/- BMDC we could successfully knock-down 
S1PR1 mRNA levels by transfection with S1PR1-specific siRNA. In wt BMDC 
this led to 72 % and in FHL2-/- BMDC to 75% knock-down (Fig. 3.12 B). Now wt 
and FHL2-/- showed similar expression levels of S1PR1. Knock-down of S1PR1 
in FHL2-/- BMDC significantly reduced their migratory rate to about half of the 
FHL2-/- BMDC transfected with control siRNA, which equaled the migratory rate 
of wt BMDC (Fig 3.12 B). Interestingly, although some S1PR1 knock-down was 
achieved in wt BMDC, this did not influence their migratory rate.  
In a second approach, we used the selective S1PR1 antagonist SEW2871 
(Sanna et al., 2004) in various concentration, which leads to receptor 
internalization, to inhibit S1PR1 function in FHL2-/- BMDC (Fig. 3.12 C, upper 
panel). Again, the increased migratory rate in FHL2-/- BMDC was significantly 
reduced by S1PR1 inhibition at already low concentrations (0.1µM). At very high 
concentrations (1µM), it seemed that also migration of wt BMDC was slightly 
reduced, but not as much as in FHL2-/- BMDC. Importantly, migratory speed of 
FHL2-/- BMDC was suppressed to levels of wt BMDC.  
In addition, we stained the BMDC incubated with SEW8271 with CD86 and 
MHCII (Fig. 3.12 C, lower panel) to be sure that SEW2871 does not influence 
the maturation of BMDC and this might change their migratory behavior. 
Indeed, in this experiment the fraction of the CD86 and MHCII highly positive 
cells ranged only between 12.51 and 15.10% in all treatments, which was not 
enough to influence their migratory behavior. 
In summary, these data indicate that in FHL2-/- BMDC, repression of S1PR1 is 
lost leading to its overexpression, and that signaling via S1PR1 is responsible 
for the increased migratory phenotype of FHL2-/- BMDC. 
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Figure 3.12: Enhanced migration of FHL2-/- BMDC is due to higher levels of S1PR1. (A,B) 
4x106 day 7 wt and FHL2-/- BMDC were electroporated with either siRNA targeted against 
S1PR1 or non targeting siRNA. (A) Two days later, RNA was isolated from electroporated 
BMDC and converted to cDNA. The knock down of S1PR1 was quantified by RT-PCR. (B) In 
parallel, the electroporated BMDC were analyzed for their migratory behavior in a Transwell 
assay. (C,D) Day 7 wt and FHL2-/- BMDC were incubated for 16 h with 0, 0.1, 1 and 10µM 
SEW2871, harvested, analyzed for their migratory behavior in a Transwell assay (C), and in 
parallel for CD86 and MHCII expression by flow cytometry (D). Values are depicted as mean 
and error bars +/-SEM. Statistical significance was calculated using a Student’s t-test: NS not 
significant, *p≤ 0.05, **p≤0.01, ***p≤0.001. The data shown here is representative of three or 
more independent experiments. 
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3.9 External addition of S1P does not influence antigen uptake and 
migration of wt BMDC 
Knowing that S1PR1 is increased in FHL2-/- BMDC, which most likely leads to 
enhanced chemotaxis of FHL2-/- BMDC. We were interested in what way the 
ligand for the receptor namely S1P might have an influence on other DC 
function like antigen uptake and migration. Ligation of S1PR1 by S1P induces 
BMDC migration towards CCL19 to a small extent in a transwell assay. This 
small increase is probably due to the fact that even without the external addition 
of S1P to the culture medium, there is already S1P in the medium.  
Wt BMDCs were preincubated with S1P and then their migration was analyzed 
in a transwell assay, while S1P was still present during the migration (Fig. 3.13 
B). External addition of S1P did not change their migratory behavior. In addition 
to migration, we also wanted to check, whether S1P might impact BMDC in a 
functional assay, i.e. antigen uptake. Therefore, wt and FHL2-/- BMDC were 
preincubated with S1P. The ability to take up antigen was assayed as explained 
in section 3.6. We could not observe a difference between wt and FHL2-/- 
BMDC in their ability to take up antigen, if incubated with S1P or not (Fig. 3.13 
A). Since we could not observe any difference regarding their capability to take 
up antigen, we assume that wt and FHL2-/- BMDC after incubation with S1P 
would consequently do not show a difference in presenting antigen. This is the 
reason why we did not test, whether addition of S1P has an effect on antigen 
presentation. 
Thus, external addition of S1P did not change the phenotypes or functions of wt 
and FHL2-/- BMDC. 
Results 
 
80 
 
Figure 3.13: Migration and antigen uptake is not changed after incubation with S1P. (A,B) 
Day 7 BMDCs were incubated for 1h with 100nM S1P. Antigen uptake (A) and migration (B) 
was determined as described before, respectively. Values are depicted as mean and error bars 
+/-SEM. Statistical significance was calculated using a Student’s t-test: NS not significant, *p≤ 
0.05, **p≤0.01, ***p≤0.001. The data shown here is representative of three or more independent 
experiments. 
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4. Discussion 
 
DC reside in the periphery, where they continuously sample their environment 
for antigen, which they take up, process and display as peptides in the context 
of MHC class molecules and present to T cells in the LN. During an infection, 
DC encounter danger signals in the form of a distinct and highly conserved 
structure of a pathogen that will trigger PRRs to undergo a drastic change of 
their phenotype which ultimately will equip them as efficient APCs. They 
upregulate costimulatory and MHC molecules and increase production of 
inflammatory cytokines, which are very important for T cells to turn into 
activated effector T cells. They also change their chemokine receptor profile, i.e. 
they highly upregulate CCR7 receptor and concomitantly downregulate all other 
chemokine receptors, which aid the DC to find its way to the draining LN where 
T and B cell home, which in turn secrete the ligand for CCR7, CCL19 and 
CCL21. These chemokines are expressed by peripheral lymphatic endothelial 
cells as well as LN stroma cells and guide DCs to downstream LNs (MartIn-
Fontecha et al., 2003). This transition is accompanied by a huge change of their 
morphology of the actin cytoskeleton, which enable them to migrate very 
efficiently to the LN to interact with T cells. Given this complex life cycle, the 
ability of DCs and their progenitors to migrate throughout the body is a critical 
aspect of their immunological function. Thus, migration is a very important and 
critical part of DC function in order to exert their function as a professional APC 
and any misbalance might result in a different outcome of the immune response 
which might be detrimental for the organism (Alvarez et al., 2008).  
FHL2-/- mice display wound healing disturbance due to defective migration of 
fibroblasts (Wixler et al., 2007) and collagen metabolism (Kirfel et al., 2008). 
Nuclear expression of FHL2, high Gleason score and grade correlate with 
relapse during follow-up in prostate cancer (Kahl et al., 2006), and it is highly 
expressed in primary and metastatic colon cancer but not in normal tissues 
(Zhang et al., 2010). Furthermore, FHL2 is known to associate with actin 
cytoskeleton components (Li et al., 2001), and might influence the morphology 
of the cell (Bai et al., 2005).  
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These observations made it worth to study the role of FHL2 as a regulator of 
DC migration. Migration of DC is very important to fulfill their function as an APC 
to elicit a successful immune response during the crosstalk of T cell. For 
example, in a different mouse model, deficient of RBP-J (Feng et al., 2010), 
authors could observe the detrimental effect on tumor formation, when DCs 
show inefficient migration. The RBP-J deficient DCs expressed lower MHCII, 
CD80, CD86, and CCR7 resulting in inefficient DC migration and T cell 
activation in vitro and in vivo, so T cells did not possess efficient cytotoxicity 
against tumor cells. 
 
4.1 FHL2 is expressed in wt BMDC and localized at the membrane in 
mature DC after stimulation with CCL19 
First of all, we were interested in the localization of FHL2 within wt BMDC (Fig. 
3.2 A), because depending on the position of FHL2 within a cell it can exert two 
different mechanistically effects. In addition, we treated BMDC with LPS and 
CCL19, because both can influence the morphology and migration of DC which 
might be controlled by FHL2. In the immature culture, DCs showing an 
immature morphology characterized by filopodia formation FHL2 is located in 
the nucleus. Their large cytoplasm has filopodia structure and long dendrites, 
which are very helpful in capturing antigen (Svitkina et al., 2003). Stimulation of 
DC with LPS leads via TLR4 signaling to maturation of DC with a change in 
morphology to a smaller, veiled phenotype expressing lamellipodia, but still in 
these cells FHL2 remained in the nucleus. In addition to locomotion, CCR7 
controls several other factors of DC function: CCL19 induces the apparition of 
dendritic protrusions in DC (Yanagawa and Onoe, 2002), indicating that CCR7 
can regulate the cytoarchitecture probably by controlling the actin cytoskeleton. 
The same authors reported that the stimulation of CCR7 with ligands CCL19 
and CCL21 positively regulates the rate of endocytosis of the mature DCs with 
concomitant up-regulation of Cdc42 and Rac activities (Yanagawa and Onoe, 
2003). The same observation holds true for CCL19 treatment in our BMDC 
culture in combination with LPS treatment, where also the cytoarchitecture and 
localization of FHL2 changed dramatically. Now, FHL2 cannot be seen in the 
nucleus anymore, instead can be found at the membrane. FHL2 is known to be 
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associated with focal adhesions which are at the cell membrane making 
attachment to ECM, but since DC are devoid of focal adhesion, we would 
surmise these are podosomes that FHL2 rather associates to in DC. In the 
mature fraction of BMDC, FHL2 seems to move after CCL19 ligand binding out 
of the nucleus to the cell membrane, where it plays a different function, 
necessary for a DC to migrate to the LN after antigen uptake. 
 
Before we focus on our main issue the loss of FHL2 in DC migration in FHL2 
deficient mice to better answer our question how FHL2 impacts DC migration, 
we checked how FHL2 was expressed in wt BMDC and wanted to be sure that 
FHL2 is missing in FHL2 deficient BMDC. By RT-PCR (Fig. 3.2 B) as well as 
Western Blot (Fig. 3.2 C) we could show that FHL2 is lost in the KO mouse. 
FHL2 is completely lost in several organs like heart, colon, lung, muscle tissue 
and BMDC from KO mice shown by RT-PCR. Low levels expression of FHL2 in 
wt BMDC and lung compared to heart, colon and muscle can be observed on 
mRNA level. 
Western Blot analysis showed expression of FHL2 in heart tissue of wt mouse 
and absence of FHL2 in KO mouse proving that FHL2 is not present in the KO 
mouse. However, Western Blot failed to detect FHL2 in wt BMDC. There are 
possible explanations: First of all, FHL2 is highly expressed in heart tissue 
(Chan et al., 1998; Genini et al., 1997) and FHL2 is expressed in BMDC at 
lower levels compared to other organs as shown by RT-PCR which makes 
detection difficult. Wixler et al. (2000) were not able to detect FHL2 reliably in 
various other cell types or tissues other than heart. They reasoned that FHL2 
exhibits a different conformational state under experimental conditions so that 
the antibody cannot bind. They also stated that binding of FHL2 to integrins 
which are incorporated in the cell membrane is very tight. After lysis of BMDC to 
get access to the proteins, the whole sample is centrifuged to remove cell 
debris. So, FHL2 could still be bound to the cell membrane, which is not loaded 
on SDS-PAGE. For these reasons we concentrated FHL2 by IP with a 
polyclonal antibody in wt and FHL2-/- lysate of BMDC (Fig. 3.2 D) and loaded 
the enriched FHL2 on SDS-PAGE gel. Here we could detect FHL2 on protein 
level in wt BMDC, which was lost in FHL2-/- DC. So, FHL2 is expressed in wt 
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DC, but only in very small amounts, which is still sufficient leading to a different 
phenotype. 
 
4.2 Increased migration of FHL2-/- is not due to different expression 
levels of CCR7 
We answered the migration issue in a first experiment by timelapse microscopy. 
We observed that FHL2-/- deficient BMDC exhibited significant higher migratory 
speed on collagen coated surface than wt BMDC towards a CCL19 chemokine 
gradient (Fig. 3.3 A). Moreover, we could demonstrate that FHL2-/- BMDC 
travel with enhanced directionality and persistence (Fig.3.3 B) compared to wt 
BMDC. The difference in migratory speed between FHL2-/- and wt BMDC 
shown by timelapse microscopy could be confirmed by transwell assay towards 
CCL19 (Fig. 3.4 A).  
On possible explanation for observed enhanced migratory phenotype of BMDC 
lacking FHL2 is the upregulation of the CCR7 receptor, which is highly 
expressed in mature and fast migrating cells. Furthermore in mature DC ligand 
binding of CCL19 made FHL2 translocate from the nucleus to occur at the cell 
membrane (Fig. 3.2 A). CCR7 is not only the guide for the DC, it is also the 
accelerator for DC migration (Dieu et al., 1998; Sozzani et al., 1998). CCR7 
regulates in DC two signaling modules, one formed by Gi and a specific 
hierarchy of MAPK family members that regulates chemotaxis and another 
formed by Rho/Pyk2/cofilin that regulates the migratory speed of DCs. 
Therefore, the stimulation of CCR7 by its ligand leads to an increase in the 
activity of these signaling molecules and consequently to an increase in the 
migratory speed of the cells. The stimulation by CCR7 ligands of the intrinsic 
migratory speed axis behaves as an accelerator system that increases the 
speed at which DCs move toward the maximum concentrations of CCL19 and 
CCL21. In the in vivo context, this regulatory process would have the obvious 
advantage of more rapidly directing DCs to LN regions. FHL2 could be involved 
in this process acting as a co-activator of transcription factor of CCR7. Since we 
could not see any differences in CCR7 expression levels (Fig. 3.5 A), it does not 
seem that FHL2 acting as transcriptional co-activator has an influence on the 
expression levels of CCR7. So, all the previously described potential roles of 
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CCR7 increasing DC migration does not take place in our FHL2-/- model. So, 
another mechanism must be responsible for it. Even treatment with LPS and 
TNF-α (Fig. 3.5 B) could not change expression levels of CCR7 between wt and 
FHL2-/- BMDC, although the overall expression level was increased compared 
to immature DC. 
 
The passage of leukocytes through basement membranes involves proteolytic 
degradation of extracellular matrix (ECM) components executed by focalized 
proteolysis where matrix metalloproteinases (MMPs) are engaged. They were 
demonstrated to degrade and remodel numerous ECM components (Abecassis 
et al., 2003; Park et al., 2008), and thereby being important for the regulation of 
cellular functions, e.g. migration (Di Girolamo et al., 2006; Ratzinger et al., 
2002). ADAM-17 and FHL2 colocalize with the actin-based cytoskeleton that 
suggests that FHL2 might have a role in the regulation of ADAM-17 (Canault et 
al., 2006); and FHL2-/- mesenchymal stem cells show perturbed organization of 
ECM (Park et al., 2008). Maybe this would change the outcome for the 
migration of FHL2-/- BMDC in vivo compared to the in vitro situation, where we 
could see enhanced migration of FHL-/- BMDC. We could verify increased 
migratory speed of BMDC deficient of FHL2 in vivo by injection of unstimulated 
or TNF-α stimulated FHL2-/- and wt BMDC into the footpad of wt mice (Fig. 3.6 
A). So, in our mouse model, in vivo migration showed the same result as in 
vitro, i.e. FHL2-/- BMDC migrate faster than wt BMDC. It seems like that FHL2-
/- BMDCs do not alter their in vivo environment by e.g. ECM remodeling as 
proposed before in such a way that FHL2-/- BMDC behave complete differently 
with respect to migration: They were not slower or showed similar migration 
level. Maybe it had an effect in vivo, so that migration was amplified, but it is 
really hard to compare. Interestingly, the difference between wt and FHL2-/- 
BMDC was bigger when treated with TNF-α than not stimulated. Somehow, 
TNF-α amplified the phenotypical effects on FHL-/- BMDC. ADAM-17 mediates 
release of TNF from the cell surface (Black et al., 1997). Less ADAM-17 was 
detected at the surface of wt mouse macrophages compared to FHL2 deficient 
macrophages. Maybe, there is a connection between TNF-α signaling and 
FHL2 via ADAM-17. Although we never directly in one single experiment 
compared migratory velocities of immature and mature DCs in vivo, we would 
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expect that also here TNF-α matured DCs showed higher migration levels 
compared to immature DCs as determined by other groups (De Vries et al., 
2003).  
 
But maybe we were able to obtain more FHL2-/- BMDC from the LN, because 
FHL2 has an anti-apoptotic effect, which prevents BMDC deficient of FHL2 to 
die in contrast to wt BMDC. FHL2 is known to regulate the cell cycle (Martin et 
al., 2007), so it can trigger apoptosis (Scholl et al., 2000). In several different 
cell lines FHL2 inhibited growth in vitro (Amann et al., 2010; Ding et al., 2009), 
and in colon cancer cells it Inhibited tumorigenesis in nude mice (Wang et al., 
2007). One other group (Labalette et al., 2008a; Labalette et al., 2008b) could 
even see the opposite effect: FHL2 deficiency triggers a broad change of the 
cell cycle program that is associated with down-regulation of several G(1)/S and 
G(2)/M cyclins, and DNA replication machinery, thus correlating with reduced 
cell proliferation. Nevertheless, we could neither see a beneficial or detrimental 
effect on cell viability, i.e. we could not see that FHL2 regulate these processes 
in DCs by determining the survival of wt and FHL2-/- in vitro by a MTT (Fig. 3.6 
C). Overall, all these data indicate that FHL2-/- BMDC migrate faster than wt 
BMDC in vivo.  
This is in contrast to observations made by several other groups, where loss of 
FHL2 leads to a defect in migration. In human glioblastoma cells FHL2 
knockdown by short hairpin RNA inhibited cell proliferation and migration. 
Conversely, overexpression of FHL2 stimulated the proliferation, anchorage-
independent growth, and migration of glioblastoma cells (Li et al., 2008). Also, 
FHL2 overexpression markedly accelerated cell migration, whereas FHL2 
siRNA decreased SW480 cell invasion (Zhang et al., 2010). In these studies 
loss of FHL2 lead to impaired migration (Wixler et al., 2007), whereas our 
experiments or other groups (Labalette et al., 2010) observed accelerated cell 
migration. This can be explained by the fact that FHL2 associated cell migration 
is cell type specific due to intrinsic or external factors which varies in every 
environment. But there is a difference of leukocytes or DCs from other cell types 
with respect to the mode of migration. The most primitive and effective form of 
cell migration is amoeboid movement, which mimics features of the single-cell 
behavior of the amoeba. These cells use a fast ‘crawling’ type of movement that 
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is driven by short-lived and relatively weak interactions with the substrate, which 
ends up  to move at high velocities (2–30 µm/min; Friedl et al., 1998). Amoeboid 
movement is carried out by hematopoietic stem cells, leukocytes and certain 
tumor cells. In contrast to cells that use amoeboid migration, mesenchymal cells 
accomplish the complete four-step migration sequence. In 3D tissues, 
mesenchymal cells adopt a spindle-shaped, fibroblast-like morphology, as 
characteristic for fibroblasts, myoblasts, single endothelial cells or sarcoma 
cells. The elongated morphology is dependent on integrin-mediated adhesion 
dynamics and the presence of high traction forces on both cell poles (Friedl, 
2004).  
 
Integrin adhesion receptors are heterodimeric glycoproteins which are 
composed of noncovalently associated α and β transmembrane subunits (Lad 
et al., 2007). Integrins play a very important role for cell migration, since ligand 
binding to integrins leads to integrin clustering and recruitment of actin filaments 
and signalling proteins to the cytoplasmic domain of integrins (Brakebusch and 
Fassler, 2003). FHL2 also interacts with several integrins (Samson et al., 2004; 
Wixler et al., 2000). It was demonstrated integrins are involved in DC migration 
(van Helden et al., 2006). This contradicts to murine leukocytes, where all 
integrins heterodimers were ablated and that functional integrins do not 
contribute to migration in three-dimensional environments (Lammermann et al., 
2008). Instead, these cells migrate by the sole force of actin-network expansion, 
which promotes protrusive flowing of the leading edge. Therefore we did not 
check, if integrin signaling is involved in FHL2-/- BMDC migration. Although as 
determined in later conducted experiments: DCs without integrins could switch 
to a different migration mode (Quast et al., 2009; Renkawitz et al., 2009), and 
chemotactic DCs mechanically adapt to the adhesive properties of their 
substrate by switching between integrin-mediated and integrin-independent 
locomotion (Renkawitz et al., 2009).  
 
 
Discussion 
 
88 
4.3 FHL2-/- BMDC have more lamellipodia due to elevated levels of 
Rac1 
After taking up antigen and PRR signaling has been triggered, DC go through a 
lot of changes converting them from a drinking cell to an highly efficient antigen 
presenting cell (Norbury, 2006). To fulfill this task they have to transport the 
antigen to the LN swiftly, therefore also the actin cytoskeleton will change 
dramatically. Since reorganization of the actin cytoskeleton is the basis for 
cellular migration (Mitchison and Cramer, 1996), the cytoskeletal actin 
conformation of FHL2-/- and wt BMDC was examined by immunofluorescent 
staining with phalloidin (Fig. 3.7 A). As discussed before in section 3.1 in a 
seven day DC culture there are already a number of DCs that have matured 
spontaneously. The number of DC showing a typical more mature phenotype 
with expanding veils and lamellipodia was significant higher in the DC culture 
derived from FHL2-/- mouse than wt DC. Thus, FHL2 has an impact of the 
reorganization of the actin cytoskeleton, which probably contributes to the 
enhanced migration speed of FHL2-/- BMDC. Binding of phalloidin to F-actin 
mirrors the amount of filamentous actin which is higher in fast migrating cells 
(Fukui et al., 2001). This was quantified by intracellular staining of phalloidin in 
flow cytometry where significant higher amounts of F-actin were present in 
FHL2-/- BMDC (Fig. 3.7 B). This difference was more distinctive after 
stimulation with TNF-α, which is reflected by the in vivo migration of wt and 
FHL2-/- BMDC to popliteal LN, where the difference was higher when 
stimulated with TNF-α. It seems that TNF-α does not lead to enhanced 
maturation of FHL2-/- but is able to enhance the migratory capacity of FHL2-/- 
DC and levels of filamentous actin. Thus TNF-α seems to turn on two 
independent pathways in DC maturation: It stimulates properties necessary for 
migration, but does not induce maturation as compared e.g. LPS. Lamellipodia 
formation is caused mainly by activated Rac1, which we find higher amounts in 
FHL2-/- DC compared to wt DC. 
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4.4 FHL2-/- BMDC do not show a more mature phenotype and 
differences in antigen uptake and presentation 
To present antigens or pathogens to naive T cells, DC must mature after 
capturing and processing exogenous antigens and also provide three essential 
signals: An antigen presentation signal via an MHC-peptide complex to TCR, 
costimulatory signals e.g., CD40, CD80, and CD86, and proinflammatory 
cytokines e.g., IL-6, IL-12, and TNF-α (Lutz and Schuler, 2002). The expression 
of cell surface molecules and production of proinflammatory cytokines in DC are 
primarily regulated by NF-κB (Ouaaz et al., 2002; Rescigno et al., 1998). Thus, 
regulating NF-κB activation is of critical importance for immunoregulation and 
prevention of allograft rejection (Shinoda et al., 2010). Deficiency of FHL2 could 
influence the expression levels of costimulatory molecules by regulating NF-κB 
transcription, since nuclear translocation of the p65 subunit of NF-κB is 
enhanced in FHL2-deficient osteoclast precursors (Bai et al., 2005) and 
expression of FHL2 results in enhancement of NF-κB activation (Stilo et al., 
2002). After antigen uptake and processing, peptide is loaded on MHC and 
transported to the surface of the cell ready to communicate with T cells. 
Shuttling of MHC to cell surface also depends on the dynamics of the actin 
cytoskeleton and activation of small Rho GTPases like Rac1, and both incidents 
are different in FHL2-/- DC (Erickson et al., 1996; Turley et al., 2000; Luna et 
al., 2002). 
Maybe all the processes are changed in FHL2-/-BMDC and influence the 
maturation state. We found that the maturation markers such as MHCI, MHCII, 
CD80, CD86 and CD40 are expressed to similar level between FHL2-/- and wt 
BMDC (Fig. 3.8 A). After incubation with TNF-α, these markers were elevated to 
similar degree in FHL2-/- and wt BMDC. Even a higher expression was 
observed when BMDC were stimulated with LPS (Efron et al., 2005; Granucci et 
al., 2001). Thus, it seems that NF-κB signaling is not altered in FHL2-/- BMDC, 
which could have influenced the expression levels of costimulatory molecules. 
In order to determine, if NF-κB signaling is different in FHL2-/- BMDC, a further 
number of experiment, e.g. by Western Blot is required. Also Qiao et al., 2009 
failed to show a direct association of FHL2 with nuclear NF-κB in 
gastrointestinal cancer. Although the actin cytoskeleton is differentially arranged 
Discussion 
 
90 
in FHL2-/- BMDC this did not seem to affect transport of MHC class molecules 
to the surface. 
As a third signal DC provide soluble molecules to the T cell like IL-12 and TNF-
α to turn them into effector T cells. Differential production of IL-12 would rather 
lead to a Th1 phenotype during the crosstalk of DC and T cell (Macatonia et al., 
1995), and this effect is even enhanced by administration of LPS (Mellman and 
Steinman, 2001). Induction of IL-12 occurs in response to signals that require 
either p50 or cRel NF-κB family members (Murphy et al., 1995; Zhang et al., 
2000). DC-derived TNF-α is responsible for the development of IL-10-producing 
CD4+ regulatory T cells by immature DCs (Hirata et al., 2010). Another study 
confirmed this in vivo, where stimulation by TNF-α results in incompletely 
matured DCs (semi-mature DCs) which induce peptide-specific IL-10-producing 
T cells in vivo and prevent experimental autoimmune encephalomyelitis 
(Menges et al., 2002). But also here we could not observe any difference 
between wt and FHL2-/- DC with respect to production of IL-12 and TNF-α and 
also not after additional stimulation with LPS (Fig. 3.9 B). Incubation of BMDC 
with TNF-α did not induce secretion of IL-12 and TNF-α, which was speculated 
to be the reason that TNFα- matured DC rather induce tolerance (Menges et al., 
2002). Hence, we assume that increased migration in FHL2-/- is not due to a 
constitutive maturation of BMDC. FHL2 does not influence the maturation status 
of DC, but according to our until now conducted experiments migration of 
BMDC.  
 
The main task of DC is to present antigen to T cells after they have taken it up 
in the periphery, which will lead to an efficient immune response or tolerance 
depending on the signals provided by DC. Although we know that these signals 
i.e. maturation markers and cytokine production are not different, there still can 
be a difference regarding antigen uptake and presentation between wt and 
FHL2-/- DC, because also organization of the cytoskeleton influences the 
process of antigen uptake and presentation. Macropinocytosis and endocytosis 
are related processes, both depending on regulated actin assembly and thus 
the activity of the Rho family GTPases Cdc42 and Rac (Garrett et al., 2000; 
West et al., 2000). DCs have many routes to take up antigen either by 
macropinocytosis e.g dextran or receptor mediated like OVA. When feeding 
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both types of DC with OVA or dextran, we could not observe any difference in 
uptake (Fig. 3.10 A). Although FHL2 contributes to the organization of the 
cytoskeleton, this change does not seem relevant in the process of antigen 
uptake. We know that FHL2 has an influence on cell morphology and 
organization of the cytoskeleton, which is crucial in taking up antigen and in the 
crosstalk between DC and T cell. Selective Rac1 inhibition in DCs diminishes 
apoptotic cell uptake and cross-presentation in vivo (Benvenuti et al., 2004). 
Inhibition of the Rac-Cdc42-Ral pathway markedly reduces dendritic probings 
as well as short and long-term contacts with T cells in vitro (Swetman et al., 
2002). Rac1 signaling, which is enhanced in FHL2-/- BMDC, did not seem to 
play a role regarding antigen presentation in FHL2-/- BMDC. This we could 
observe for presenting the model antigen OVA to OVA specific T cells in a co-
culture, when we looked for proliferation of T cells by CFSE dilution and IL-2 
production (Fig. 3.10 B, C and D). 
 
4.5 S1PR1 expression is increased in FHL2-/- BMDC 
Ligand binding by S1P plays a role in FHL2 signaling in several cell lines 
leading to a translocation of FHL2 in the nucleus (Muller et al., 2002). 
Additionally, S1PR are differentially expressed in mature DC, which also have 
faster migrating abilities than immature DC, showing high expression levels of 
S1PR1 and 3 and diminished or steady expression of S1PR2 and 4 (Czeloth et 
al., 2005). Furthermore, CHO cells overexpressing S1PR1 and 3 show higher 
migration levels than their controls (Okamoto et al., 2000). All this made us 
elucidate the expression levels of S1PR further, because this might explain the 
increased migration behavior noticed in FHL2-/- DC. Indeed, we could detect 
higher expression levels of S1PR1 in FHL2-/- DC determined by qRT-PCR, and 
this effect was even more pronounced after stimulation with TNF-α (Fig. 3.10). 
The expression of S1PR2-4 does not seem to be different between wt and 
FHL2-/- BMDC and show differential expression levels to the same extent after 
incubation with TNF-α compared to non-treated, which is in accordance to the 
observations of other groups (Maeda et al., 2007; Rathinasamy et al., 2010).  
We could confirm this observation more functionally in a migration assay after 
knockdown of S1PR1 by electroporation with S1PR1 specific siRNA: S1PR1 
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loss reversed the phenotype of FHL2-/- BMDC (Fig. 3.13 A and B). We wanted 
to explore this further with the help of a specific small molecular inhibitor against 
S1PR1 SEW2871, which can have an agonistic or antagonistic effect on 
S1PR1. On the one hand cells including DC tend to migrate towards SEW2871, 
but on the other hand incubation of cells with it leads to internalization of S1PR1 
which is not fully functional anymore (Sanna et al., 2004). This happened when 
incubating SEW2871 with FHL2-/- DC which lead to slower migration compared 
to control and approaching the migration levels of wt DC (Fig. 3.12 C). We could 
exclude that SEW2871 itself might have an effect on the maturation status of 
BMDC, which could also cause differential migration capabilities of BMDC. 
Thus, S1PR1 must play a role in FHL2 signaling causing accelerated DC 
migration ability, but does not have an impact on several other DC functions like 
antigen uptake and presentation. But these processes seem to be regulated by 
other S1PRs like 3 rather than S1PR1 (Maeda et al., 2007), and endocytosis 
seems mainly to be controlled by Cdc42, which we did not look for. S1P by itself 
did not change antigen uptake ability (Fig. 3.13 A) or migration status (Fig. 3.13 
B) by immature DC, which fits to the observations made by (Maeda et al., 
2007), who did not observe that S1P affected mature DC regarding these 
processes. 
 
4.6 Summary  
Our observation suggests the following mechanism in FHL2-/- BMDC. We think 
that in FHL2-/- BMDC the following chain of events are occurring based on a 
combination of our findings and literature: Immature DC show high expression 
levels of S1PR2 (Czeloth et al., 2005) and signaling via S1PR2 by S1P, which 
is present in the serum supplemented to the media, leads to RhoA mediated 
FHL2 translocation into the nucleus (Muller et al., 2002). Being able to bind to 
proteins it will bind to an unknown transcription factor acting in this setting as a 
co-repressor of transcription of S1PR1 which we know is quite low in immature 
DC. This is supported by the fact that we mainly find FHL2 in the nucleus in 
immature BMDC. At the same time, residing in the periphery with slight 
expression of CCR7 it cannot respond to CCL19, therefore not being able to 
migrate quickly (Fig. 4.1 A). 
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We propose that in the KO setting the same scenario is taking place after a DC 
has matured after PRR stimulation (Fig. 4.1 B). In a mature DC signaling via 
S1PR2 by S1P declines, so no FHL2 is present in the nucleus inhibiting the 
transcription of S1PR1, which is increased in mature DC. We know that in 
mature DCs after ligand binding with CCL19 FHL2 is not present in the nucleus 
anymore, but can be found at the cell membrane. The same is true for KO DC 
where no FHL2 is present in the nucleus. S1PR1 lead via Gi receptor to higher 
amounts of Rac1 which entail lamellipodia formation and in the end increased 
migration (Takuwa, 2002).  
Literature hints that it is most likely S1PR2 working upstream of FHL2, but this 
theory has to be confirmed by e.g. knock down of S1PR2 and as a read out 
followed by a migration assay. In order to fortify the underlying mechanism it 
would be sufficient finding the missing link in the regulation of S1PR1 
transcription by FHL2. There is a pile of literature hinting to Forkhead Box O1 
(Foxo1) being the transcription factor for S1PR1. FHL2 inhibits Foxo4 (Shi et 
al., 2010) and Foxo1 transcriptional activity in prostate cancer cells by 
promoting the deacetylation of Foxo1 by Sirtuin1 (SIRT1; Yang et al., 2005). In 
quiescent T cells, nonphosphorylated active Foxos maintain expression of  
Kruppel-like factor 2 (KLF2), that regulates expression CCR7 and S1PR1 
(Finlay and Cantrell, 2010). Taken together, these results suggested that Foxo3 
may control expression of S1PR1. Indeed, there was a small, but consistent, 
reduction in S1PR1 mRNA in Foxo3−/− B cells to ∼75% of wt levels (Hinman et 
al., 2009). They demonstrate using transcriptional profiling that Foxo1 also 
increases transcripts of S1PR1 and 4 (Fabre et al., 2008). 
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Figure 4.1: Model of FHL2-mediated repression of S1PR1 expression and regulation of 
DC migration. (A) In immature wt DCs, signaling via S1PR2 leads to Rho activation, causing 
translocation of FHL2 into the nucleus, where FHL2 represses transcription of S1PR1 by 
binding to the transcription factor of the promoter region. Additionally, low expression levels of 
CCR7 blocks Rac activity. (B) Maturation of DCs leads to downregulation of S1PR2. 
Subsequent diminished Rho activation inhibits nuclear translocation of FHL2 into the nucleus, 
which has the same effect as FHL2 deficiency (i.e. reduced repression of S1PR1 transcription). 
S1P signaling via greater S1PR1 levels increases Rac activation, which leads to an increased 
migratory rate of mature or FHL2-/- DCs. 
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4.7 Conclusion 
The interaction of DC with naive T cells can lead to different forms of immune 
responses ranging from immunity or to T-cell tolerance, depending on the type 
of DC and its activation state (Shortman and Naik, 2007). The common view 
supposes that immature DC induce tolerance, whereas mature DC induce 
immunity to antigens (Sousa, 2006). The question is what the outcome would 
be in FHL2-/- BMDC or in FHL2-/- mice or would it be any different compared to 
wt DC? And how can we you use this information? Fainaru et al. (2005) 
reported that in Runx3 KO mice, expression of CCR7 is enhanced, resulting in 
increased migration of alveolar DC to the lung-draining LN. This increased DC 
migration and the consequent accumulation of activated DC in draining LN is 
associated with the development of asthma-like features. But they also showed 
higher expression levels of CD86 and MHCII what drove the T cells to a more 
activated state. However wt and FHL2-/- BMDC are equally mature. On the 
other hand disordered migratory DC cannot mount an effective T cell mediated 
specific immune response as seen in PI3K−/− DCs, which migrate poorly 
towards chemotactic factors in vitro and in vivo, leading to defective cutaneous 
hypersensitivity responses (Del Prete et al., 2004). FHL2-/- BMDCs are a very 
helpful model to study how migration influences T cell activation based on their 
migration on not what additional factors like maturation status or antigen 
presentation capabilities they are providing during the crosstalk of T cells. We 
postulate that FHL2-/- DC are able to induce tolerance to antigens, because 
immature FHL2-/- DC reach the LN earlier than wt DC and most likely cannot 
deliver an activation signal to antigen-specific T cells because of a lack of 
costimulatory molecules. FHL2-/- BMDC could serve as a convenient model to 
investigate the induction of tolerance to T cells. The role of migration of DC in a 
lot of diseases and tumor models can be studied on the basis of FHL2-/- BMDC, 
and the effect seen is only due to the enhanced migration of DC. If this is the 
case inhibition of FHL2 could be used as a therapeutic target  
Testing this hypothesis needs more complex in vivo experiments, and therefore 
it is necessary to look for altered ability in antigen uptake and presentation in 
FHL2-/- BMDC in contrast to wt BMDC in vivo. Because it is important to know 
that the effect seen in these kinds of experiments is only due the enhanced 
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migration of FHL2-/- BMDC. The current model of FHL2 signaling is 
recommended in Fig. 4.1. 
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